WO2018041122A1 - 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用 - Google Patents
氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用 Download PDFInfo
- Publication number
- WO2018041122A1 WO2018041122A1 PCT/CN2017/099579 CN2017099579W WO2018041122A1 WO 2018041122 A1 WO2018041122 A1 WO 2018041122A1 CN 2017099579 W CN2017099579 W CN 2017099579W WO 2018041122 A1 WO2018041122 A1 WO 2018041122A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- formula
- cycloalkyl
- alkyl
- Prior art date
Links
- 0 CC(C(C1=CCC(*(*)*)=CC=C1C(*)=O)=C1)=CN([C@@](*)C(Nc(cc2)ccc2C(O)=O)=O)C1=O Chemical compound CC(C(C1=CCC(*(*)*)=CC=C1C(*)=O)=C1)=CN([C@@](*)C(Nc(cc2)ccc2C(O)=O)=O)C1=O 0.000 description 13
- ZRWSZWXTBXVMGS-UHFFFAOYSA-N CC(c(c(C(C(OC)=CN1C(Cc2ccccc2)C(Nc2ccc3[nH]c(C(F)(F)F)nc3c2)=O)=CC1=O)c1)ccc1Cl)=O Chemical compound CC(c(c(C(C(OC)=CN1C(Cc2ccccc2)C(Nc2ccc3[nH]c(C(F)(F)F)nc3c2)=O)=CC1=O)c1)ccc1Cl)=O ZRWSZWXTBXVMGS-UHFFFAOYSA-N 0.000 description 2
- KTXMVRBNCXBZGX-UHFFFAOYSA-N CC(C(C(C(F)(F)F)=C1)=CCC1N)=O Chemical compound CC(C(C(C(F)(F)F)=C1)=CCC1N)=O KTXMVRBNCXBZGX-UHFFFAOYSA-N 0.000 description 1
- GGVCZXSRSNODLM-UHFFFAOYSA-N CC(C)(C)OCCC(C(Nc(cc1CN2)ccc1C2=O)=O)N(C=C(C(c1cc(Cl)ccc1C(C)=O)=C1)OC)C1=O Chemical compound CC(C)(C)OCCC(C(Nc(cc1CN2)ccc1C2=O)=O)N(C=C(C(c1cc(Cl)ccc1C(C)=O)=C1)OC)C1=O GGVCZXSRSNODLM-UHFFFAOYSA-N 0.000 description 1
- AUFSAJVCWCOKMO-UHFFFAOYSA-N CC(C)(C)OCCC(C(Nc1cc(Cl)cnc1)=O)N(C=C(C(c1cc(Cl)ccc1C(C)=O)=C1)OC)C1=O Chemical compound CC(C)(C)OCCC(C(Nc1cc(Cl)cnc1)=O)N(C=C(C(c1cc(Cl)ccc1C(C)=O)=C1)OC)C1=O AUFSAJVCWCOKMO-UHFFFAOYSA-N 0.000 description 1
- SNMBYILYHVLGDA-DEOSSOPVSA-N CC(C)(C)OCC[C@@H](C(Nc(cc1)ccc1C(O)=O)=O)N(C=C(C(c1cc(Cl)ccc1C(C)=O)=C1)OC)C1=O Chemical compound CC(C)(C)OCC[C@@H](C(Nc(cc1)ccc1C(O)=O)=O)N(C=C(C(c1cc(Cl)ccc1C(C)=O)=C1)OC)C1=O SNMBYILYHVLGDA-DEOSSOPVSA-N 0.000 description 1
- SNMBYILYHVLGDA-XMMPIXPASA-N CC(C)(C)OCC[C@H](C(Nc(cc1)ccc1C(O)=O)=O)N(C=C(C(c(cc(cc1)Cl)c1C(C)=O)=C1)OC)C1=O Chemical compound CC(C)(C)OCC[C@H](C(Nc(cc1)ccc1C(O)=O)=O)N(C=C(C(c(cc(cc1)Cl)c1C(C)=O)=C1)OC)C1=O SNMBYILYHVLGDA-XMMPIXPASA-N 0.000 description 1
- QYKMNJJKVQYERA-UHFFFAOYSA-N CC(c(c(C(C(OC)=CN1C(CC2CCC2)C(Nc(cc2)ccc2C(O)=O)=O)=CC1=O)c1)ccc1Cl)=O Chemical compound CC(c(c(C(C(OC)=CN1C(CC2CCC2)C(Nc(cc2)ccc2C(O)=O)=O)=CC1=O)c1)ccc1Cl)=O QYKMNJJKVQYERA-UHFFFAOYSA-N 0.000 description 1
- YMOHOFMTHPBHHT-UHFFFAOYSA-N CC(c(c(C(C(OC)=CN1C(Cc(cc2)ccc2Cl)C(Nc(cc2)ccc2C(O)=O)=O)=CC1=O)c1)ccc1Cl)=O Chemical compound CC(c(c(C(C(OC)=CN1C(Cc(cc2)ccc2Cl)C(Nc(cc2)ccc2C(O)=O)=O)=CC1=O)c1)ccc1Cl)=O YMOHOFMTHPBHHT-UHFFFAOYSA-N 0.000 description 1
- WMSOVTFORZMZJK-UHFFFAOYSA-N CC(c(c(C(C(OC)=CN1C(Cc(cc2)ccc2NC(C)=O)C(Nc(cc2)ccc2C(O)=O)=O)=CC1=O)c1)ccc1Cl)=O Chemical compound CC(c(c(C(C(OC)=CN1C(Cc(cc2)ccc2NC(C)=O)C(Nc(cc2)ccc2C(O)=O)=O)=CC1=O)c1)ccc1Cl)=O WMSOVTFORZMZJK-UHFFFAOYSA-N 0.000 description 1
- PZQZGEDDTONPTJ-UHFFFAOYSA-N CC(c(c(C(C(OC)=CN1C(Cc2c[n](C)nc2)C(Nc(cc2)ccc2C(O)=O)=O)=CC1=O)c1)ccc1Cl)=O Chemical compound CC(c(c(C(C(OC)=CN1C(Cc2c[n](C)nc2)C(Nc(cc2)ccc2C(O)=O)=O)=CC1=O)c1)ccc1Cl)=O PZQZGEDDTONPTJ-UHFFFAOYSA-N 0.000 description 1
- QTNQOALCNYRULC-UHFFFAOYSA-N CC(c(c(C(C(OC)=CN1C(Cc2ccccc2)C(Nc2ccc(C(N)=O)nc2)=O)=CC1=O)c1)ccc1Cl)=O Chemical compound CC(c(c(C(C(OC)=CN1C(Cc2ccccc2)C(Nc2ccc(C(N)=O)nc2)=O)=CC1=O)c1)ccc1Cl)=O QTNQOALCNYRULC-UHFFFAOYSA-N 0.000 description 1
- VADZLOZSLHZMFP-UHFFFAOYSA-N CC(c(c(C(C(OC)=CN1C(Cc2ccccc2)C(Nc2ccc(c(C#N)c[nH]3)c3c2)=O)=CC1=O)c1)ccc1Cl)=O Chemical compound CC(c(c(C(C(OC)=CN1C(Cc2ccccc2)C(Nc2ccc(c(C#N)c[nH]3)c3c2)=O)=CC1=O)c1)ccc1Cl)=O VADZLOZSLHZMFP-UHFFFAOYSA-N 0.000 description 1
- ZNGDNNOMEIEEPP-UHFFFAOYSA-N CC(c(c(C(C(OC)=CN1C(Cc2ccn[o]2)C(Nc(cc2)ccc2C(O)=O)=O)=CC1=O)c1)ccc1Cl)=O Chemical compound CC(c(c(C(C(OC)=CN1C(Cc2ccn[o]2)C(Nc(cc2)ccc2C(O)=O)=O)=CC1=O)c1)ccc1Cl)=O ZNGDNNOMEIEEPP-UHFFFAOYSA-N 0.000 description 1
- HYICPVKSKKUBCM-UHFFFAOYSA-N CC(c(ccc(Cl)c1)c1C(C(OC)=CN1C(Cc2ccccc2)C(O)=O)=CC1=O)=O Chemical compound CC(c(ccc(Cl)c1)c1C(C(OC)=CN1C(Cc2ccccc2)C(O)=O)=CC1=O)=O HYICPVKSKKUBCM-UHFFFAOYSA-N 0.000 description 1
- MMWUEMWAZJJQOA-UHFFFAOYSA-N CC(c(ccc(Cl)c1)c1C(C(OC)=CN1C(Cc2n[n](C3CC3)cc2)C(Nc2ccc3ncncc3c2)=O)=CC1=O)=O Chemical compound CC(c(ccc(Cl)c1)c1C(C(OC)=CN1C(Cc2n[n](C3CC3)cc2)C(Nc2ccc3ncncc3c2)=O)=CC1=O)=O MMWUEMWAZJJQOA-UHFFFAOYSA-N 0.000 description 1
- OOHYAQOKIOUNIA-UHFFFAOYSA-N CCC(c(c(C(C(OC)=CN1C(CCOC(C)(C)C)C(Nc(cc2)cc3c2nc(C)c(C)n3)=O)=CC1=O)c1)ccc1Cl)=O Chemical compound CCC(c(c(C(C(OC)=CN1C(CCOC(C)(C)C)C(Nc(cc2)cc3c2nc(C)c(C)n3)=O)=CC1=O)c1)ccc1Cl)=O OOHYAQOKIOUNIA-UHFFFAOYSA-N 0.000 description 1
- HDOWLYCYFRSFNK-UHFFFAOYSA-N CCC(c(c(C(C(OC)=CN1C(CCOC(C)(C)C)C(Nc2c[s]c(C(O)=O)c2)=O)=CC1=O)c1)ccc1Cl)=O Chemical compound CCC(c(c(C(C(OC)=CN1C(CCOC(C)(C)C)C(Nc2c[s]c(C(O)=O)c2)=O)=CC1=O)c1)ccc1Cl)=O HDOWLYCYFRSFNK-UHFFFAOYSA-N 0.000 description 1
- HOPAKPMSXGTEOR-UHFFFAOYSA-N CCC(c(c(C(C(OC)=CN1C(CCOC(C)(C)C)C(Nc2ccc3nccnc3c2)=O)=CC1=O)c1)ccc1Cl)=O Chemical compound CCC(c(c(C(C(OC)=CN1C(CCOC(C)(C)C)C(Nc2ccc3nccnc3c2)=O)=CC1=O)c1)ccc1Cl)=O HOPAKPMSXGTEOR-UHFFFAOYSA-N 0.000 description 1
- URWDPFQYGVUECB-DEOSSOPVSA-N CCC(c(c(C(C(OC)=CN1[C@@H](CCOC(C)(C)C)C(Nc(cc2)ccc2C(O)=O)=O)=CC1=O)c1)ccc1Cl)=O Chemical compound CCC(c(c(C(C(OC)=CN1[C@@H](CCOC(C)(C)C)C(Nc(cc2)ccc2C(O)=O)=O)=CC1=O)c1)ccc1Cl)=O URWDPFQYGVUECB-DEOSSOPVSA-N 0.000 description 1
- URWDPFQYGVUECB-XMMPIXPASA-N CCC(c(c(C(C(OC)=CN1[C@H](CCOC(C)(C)C)C(Nc(cc2)ccc2C(O)=O)=O)=CC1=O)c1)ccc1Cl)=O Chemical compound CCC(c(c(C(C(OC)=CN1[C@H](CCOC(C)(C)C)C(Nc(cc2)ccc2C(O)=O)=O)=CC1=O)c1)ccc1Cl)=O URWDPFQYGVUECB-XMMPIXPASA-N 0.000 description 1
- AVSVJSGDSPDFLH-UHFFFAOYSA-N FC(Cc1ccccc1)(F)F Chemical compound FC(Cc1ccccc1)(F)F AVSVJSGDSPDFLH-UHFFFAOYSA-N 0.000 description 1
- CKEKFQLHCAZGSP-UHFFFAOYSA-N Nc1ccc2[nH]c(C(F)(F)F)nc2c1 Chemical compound Nc1ccc2[nH]c(C(F)(F)F)nc2c1 CKEKFQLHCAZGSP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention relates to a novel class of oxopyridamide derivatives, a process for the preparation thereof, and a pharmaceutical composition containing the same, and as a therapeutic agent, in particular as an inhibitor of Factor XIa (Factor XIa, abbreviated as FXIa) and in preparation Use in medicines for the treatment and prevention of diseases such as thromboembolism.
- a novel class of oxopyridamide derivatives a process for the preparation thereof, and a pharmaceutical composition containing the same, and as a therapeutic agent, in particular as an inhibitor of Factor XIa (Factor XIa, abbreviated as FXIa) and in preparation Use in medicines for the treatment and prevention of diseases such as thromboembolism.
- Factor XIa Factor XIa
- cardiovascular and cerebrovascular diseases such as cerebrovascular, cerebral infarction, myocardial infarction, coronary heart disease and arteriosclerosis take nearly 12 million lives, which is close to 1/4 of the world's total death toll, becoming the number one enemy of human health.
- the number of people dying from cardiovascular disease in China each year is more than 2.6 million, and 75% of surviving patients are disabled, and more than 40% of them are severely disabled.
- the problem of thrombosis caused by cardiovascular and cerebrovascular diseases and diabetes and its complications has become an urgent problem to be solved today.
- Human blood coagulation is composed of an intrinsic pathway, an extrinsic pathway, and a common pathway (Annu. Rev. Med. 2011. 62: 41–57), which is sequentially activated by multiple zymogens. The process continues to be a chain reaction that is strengthened and amplified.
- the coagulation cascade is initiated by the endogenous pathway (also known as the contact activation pathway) and the exogenous pathway (also known as the tissue factor pathway) to produce FXa, which is then produced by a common pathway to form thrombin (FIIa), which ultimately forms fibrin.
- endogenous pathway also known as the contact activation pathway
- exogenous pathway also known as the tissue factor pathway
- the endogenous pathway refers to the process by which the XII factor activates the XIa-VIIIa-Ca2 ⁇ P L complex and activates the X factor, and the exogenous coagulation pathway is released from the tissue factor (TF) to the TF-VIIaCa2+ complex.
- the process of forming and activating factor X refers to the process in which the two pathways are combined into one after the formation of factor Xa, which activates prothrombin and finally produces fibrin, where FXI is necessary for maintaining the endogenous pathway and is amplified during the coagulation cascade. Play a key role.
- thrombin In the coagulation cascade, thrombin can feedbackly activate FXI, and activated FXI (FXIa) in turn promotes the production of thrombin, which amplifies the coagulation cascade. Therefore, antagonists of FXI have been extensively developed for the treatment of various thrombi.
- FXI activity ⁇ 15U/dL Human FXI deficiency
- type C hemophilia Human FXI deficiency
- This type of patient has a mild bleed phenotype and spontaneous spontaneous bleeding. Even in the event of injury or surgery, the body's hemostatic function is not affected.
- Patients with Friend C can be pregnant normally (Arterioscler Thromb Vasc Biol. 2010; 30: 388-392). This shows that FXIa security is significantly better than FXa. Therefore, the target FXIa has become a hot research topic among major companies and research institutions.
- inhibition of FXIa factor can effectively inhibit thrombus formation, but in the case of more severe thrombosis, FXIa has little effect (Blood.
- FXIa is an emerging target, and patents which disclose compounds having FXIa inhibitory activity are disclosed in WO9630396, WO9941276, WO2013093484, WO2004002405, WO2013056060, WO2017005725, and US20050171148. Among them, only Bayer's antisense oligonucleotides (ASO) BAY-2306001 entered the clinical phase II study and achieved good results.
- ASO antisense oligonucleotides
- the present invention devises a novel small molecule FXIa antagonist having the general structure (AI) wherein R 1 is C(O)R 7 , which has a significant improvement in anticoagulant action and pharmacogen absorption activity of the entire compound.
- the compounds of the invention have higher activity than the disclosed patented compounds having a similar core structure.
- the compound of the present invention exhibits excellent anticoagulant action against human blood and has good pharmacokinetic activity, and can be used for effectively treating and/or preventing cardiovascular and cerebrovascular diseases and thrombotic symptoms.
- Ring A is an aryl or heteroaryl group
- R 1 is -C(O)R 7 ;
- R 2 are the same or different and are each independently selected from the group consisting of a hydrogen atom, a halogen, an alkyl group, a halogenated alkyl group, an alkoxy group, a halogenated alkoxy group, an amino group, a nitro group, a cyano group, a hydroxyl group, a hydroxyalkyl group, a cycloalkyl group, and a heterocyclic group. a cyclic group, an aryl group and a heteroaryl group;
- R 3 is selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, cycloalkyloxy, haloalkoxy, amino, nitro, cyano, hydroxy, hydroxyalkyl and alkylthio, wherein said alkyl group Alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl and alkylthio are optionally further selected from the group consisting of a halogen atom, a halogen, an alkoxy group, a halogenated alkoxy group, an amino group, a nitro group, a cyano group, a hydroxyl group and a hydroxyalkane group. Substituted by one or more substituents in the group;
- R 4 is selected from the group consisting of a hydrogen atom, an alkyl group, an alkoxy group, a halogenated alkyl group, a hydroxyalkyl group, a cycloalkyl group, a cycloalkyloxy group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group and the ring are The alkyl, heterocyclyl, aryl and heteroaryl are optionally further substituted with one or more R 9 substituents;
- R 5 are the same or different and are each independently selected from the group consisting of a hydrogen atom, an alkyl group, an alkoxy group, an oxo group, a halogen, a halogenated alkyl group, a halogenated alkoxy group, an amino group, a nitro group, a cyano group, a hydroxyl group, a hydroxyalkyl group, and a ring.
- alkyl Alkyl, heterocyclic, aryl, heteroaryl, -C(O)R 8 , -C(O)OR 8 , -NHC(O)R 8 , -NHC(O)OR 8 , -NR 10 R 11 , -C(O)NR 10 R 11 , -CH 2 NHC(O)OR 8 , -CH 2 NR 10 R 11 , -C(O)OCH(R 10 )R 11 and -S(O) m R 8 wherein the alkyl group is optionally further selected from the group consisting of a halogen atom, a halogen, an alkoxy group, a halogenated alkoxy group, an amino group, a nitro group, a cyano group, a hydroxyl group, a hydroxyalkyl group, -NR 10 R 11 and -NHC ( O) substituted with one or more substituents in OR 8 ;
- R 7 is selected from the group consisting of a hydrogen atom, an alkyl group, a halogenated alkyl group, an alkoxy group, a halogenated alkoxy group, an amino group, a hydroxyl group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group, wherein said alkyl group Alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally further selected from the group consisting of a hydrogen atom, a halogen atom, a halogen, an alkyl group, an alkoxy group, a halogenated alkoxy group, an amino group, a nitro group, and a cyano group.
- R 8 is selected from the group consisting of a hydrogen atom, an alkyl group, a halogenated alkyl group, a hydroxyl group, an amino group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group;
- R 9 is selected from the group consisting of a hydrogen atom, a halogen atom, a halogen, an alkyl group, an alkoxy group, a halogenated alkyl group, an amino group, a nitro group, a cyano group, a hydroxyl group, a hydroxyalkyl group, a cycloalkyl group, a cycloalkyloxy group, a heterocyclic group, Aryl and heteroaryl, wherein said cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally further selected from the group consisting of a halogen atom, a halogen, an alkyl group, an alkoxy group, a halogenated alkyl group, an amino group, a nitro group Substituting one or more substituents of cyano, hydroxy, hydroxyalkyl, cycloalkyl, cycloalkyloxy, heterocyclyl, -NHC(O)R 12
- R 10 and R 11 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a halogenated alkyl group, a cycloalkyl group, a heterocyclic group, -C(O)OR 8 and -OC(O)OR 12 , wherein The cycloalkyl and heterocyclic groups are optionally further selected from the group consisting of a halogen atom, a halogen, an alkyl group, an alkoxy group, a halogenated alkyl group, an oxo group, an amino group, a nitro group, a cyano group, a hydroxyl group, and a hydroxyalkyl group. Substituted by a plurality of substituents;
- R 12 is selected from the group consisting of a hydrogen atom, an alkyl group, an alkoxy group, a halogenated alkyl group, a halogenated alkoxy group, an amino group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group;
- R 13 is an aryl or heteroaryl group, wherein the aryl and heteroaryl are optionally further selected from the group consisting of a hydrogen atom, a halogen atom, a halogen, an alkyl group, an alkoxy group, a halogenated alkyl group, an amino group, a nitro group, and a cyano group. Substituted by one or more substituents of a hydroxy group, a hydroxyalkyl group, a cycloalkyl group, a cycloalkyloxy group, and a heterocyclic group;
- n 0, 1, 2, 3 or 4;
- n 0, 1 or 2;
- s 0, 1, 2, 3 or 4.
- the compound of the formula (AI) is a compound of the formula (I):
- L 1 is an alkylene group, wherein the alkylene group is optionally further substituted with one or more substituents of a halogen or a halogen atom;
- R 6 is selected from the group consisting of a hydrogen atom, a halogen atom, a halogen, an alkyl group, an alkoxy group, an amino group, a nitro group, a cyano group, a hydroxyl group, a hydroxyalkyl group, a cycloalkyl group, a cycloalkyloxy group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein said cycloalkyl group, heterocyclic group, aryl group and heteroaryl group are further optionally selected from the group consisting of a halogen atom, a halogen, an alkyl group, an alkoxy group, a halogenated alkyl group, an amino group, a nitro group, and a cyano group.
- R 12 is selected from the group consisting of a hydrogen atom, an alkyl group, a halogenated alkyl group, an amino group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group;
- R 13 is an aryl or heteroaryl group, wherein the aryl and heteroaryl are optionally further selected from the group consisting of a hydrogen atom, a halogen atom, a halogen, an alkyl group, an alkoxy group, a halogenated alkyl group, an amino group, a nitro group, and a cyano group. Substituted by one or more substituents of a hydroxy group, a hydroxyalkyl group, a cycloalkyl group, a cycloalkyloxy group, and a heterocyclic group;
- Ring A, R 1 to R 3 , R 5 , n and s are as defined in the formula (AI).
- the compound of the formula (AI) is a compound of the formula (Iaa):
- Rings A, L 1 , R 1 to R 3 , R 5 to R 6 , n and s are as defined in the formula (I).
- R 5 and s are as defined in the formula (AI).
- the compound of the formula (AI) is a compound of the formula (II):
- R 7 is selected from the group consisting of alkyl, cycloalkyl and haloalkyl, wherein said alkyl or cycloalkyl is optionally further substituted with one or more substituents selected from the group consisting of a halogen atom, a halogen, an alkyl group and a cycloalkyl group.
- L 1 , R 2 , R 3 , R 5 , R 6 and n are as defined in the formula (I).
- the compound of the formula (AI) wherein R 5 is the same or different and each independently selected from alkyl, alkoxy, oxo, halogen, haloalkane Base, cyano, hydroxy, -C(O)OR 8 , -NHC(O)OR 8 , -C(O)NR 10 R 11 , -CH 2 NHC(O)OR 8 , -CH 2 NR 10 R 11 , -C(O)OCH(R 10 )R 11 and -S(O) m R 8 ;
- R 8 is selected from the group consisting of a hydrogen atom, an alkyl group, a hydroxyl group, and an amino group;
- R 10 and R 11 are the same or different and are each independently Selected from a hydrogen atom, an alkyl group, a halogenated alkyl group, a cycloalkyl group, a heterocyclic group, -C(O)OR 8 and -OC(O)OR
- the compound of the formula (AI) is a compound of the formula (III):
- R 5 is the same or different and is each independently selected from the group consisting of alkyl, alkoxy, oxo, halogen, haloalkyl, cyano, hydroxy, -C(O)OR 8 , -NHC(O)OR 8 ,- C(O)NR 10 R 11 , -CH 2 NHC(O)OR 8 , -CH 2 NR 10 R 11 , -C(O)OCH(R 10 )R 11 and -S(O) m R 8 ;
- R 8 is selected from the group consisting of a hydrogen atom, an alkyl group, a hydroxyl group, and an amino group; and
- R 10 and R 11 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a halogenated alkyl group, a cycloalkyl group, a heterocyclic group, and -C(O).
- cycloalkyl and heterocyclic groups are optionally further selected from the group consisting of a halogen atom, a halogen, an alkyl group, an alkoxy group, a halogenated alkyl group, an oxo group, an amino group, a nitrate Substituted by one or more substituents of a cyano group, a cyano group, a hydroxy group and a hydroxyalkyl group; R 12 is an alkyl group;
- R 7 is selected from the group consisting of alkyl, cycloalkyl and haloalkyl, wherein said alkyl or cycloalkyl is optionally further substituted with one or more substituents selected from the group consisting of a halogen atom, a halogen, an alkyl group and a cycloalkyl group.
- L 1 , R 2 , R 3 , R 6 and n are as defined in the formula (I).
- the compound of the formula (AI) is a compound of the formula (IV):
- L 1 , R 2 , R 3 , R 6 , R 7 and n are as defined in the formula (III).
- R 14 is a hydrogen atom or a halogen atom;
- R 6 is selected from the group consisting of a hydrogen atom, a halogen atom, a halogen, an alkyl group, an alkoxy group, a cycloalkyl group, a cycloalkyloxy group, a heterocyclic group, an aryl group, and a heteroaryl group; wherein the cycloalkyl group is And a heterocyclic group, an aryl group and a heteroaryl group, optionally further selected from the group consisting of a halogen atom, a halogen, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, -NHC(O)R 12 and R 13 Or substituted with a plurality of substituent
- a heterocyclic group, an aryl group and a heteroaryl group wherein the cycloalkyl group, heterocyclic group, aryl group and heteroaryl group are further selected from a halogen atom, a halogen, an alkyl group, an alkoxy group, a cycloalkane Substituted with one or more substituents of -NHC(O)R 12 and R 13 ;
- R 12 is alkyl or cycloalkyl;
- R 13 is aryl or heteroaryl, wherein The aryl and heteroaryl groups are optionally further substituted with one or more substituents selected from the group consisting of a halogen atom, a halogen, an alkyl group, an alkoxy group, a halogenated alkyl group, an amino group, a nitro group, a cyano group, and a hydroxyl group.
- Typical compounds of the general formula (AI) include, but are not limited to:
- a tautomer a meso form, a racemate, an enantiomer, a diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
- a method of preparing a compound of the formula (AI), the method comprising:
- a compound of the formula (AI-A) and a compound of the formula (AI-B) or a hydrochloride thereof are subjected to a condensation reaction under basic conditions, optionally under basic conditions, to give a compound of the formula (AI). ;
- Ring A, R 1 to R 5 , n and s are as defined in the formula (AI).
- a compound of the formula (I-A) and a compound of the formula (AI-B) or a hydrochloride thereof are subjected to a condensation reaction under basic conditions, optionally under basic conditions, to give a compound of the formula (I);
- Rings A, L 1 , R 1 to R 3 , R 5 to R 6 , n and s are as defined in the formula (I).
- Another aspect of the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula (AI) or a tautomer thereof, a mesogen, a racemate, an enantiomer a form, a diastereomer or a mixture thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent and excipient.
- Another aspect of the invention relates to a compound of the formula (AI) or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture thereof Or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, which is used as a medicament.
- Another aspect of the invention relates to a compound of the formula (AI) or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture thereof Or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same, for use in the manufacture of a medicament for inhibiting factor XIa.
- Another aspect of the invention relates to a compound of the formula (AI) or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture thereof Or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, which is used as a XIa inhibitor.
- Another aspect of the invention relates to a compound of the formula (AI) or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture thereof Or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same, for use in the manufacture of a medicament for preventing and/or treating a XIa factor mediated disease.
- Another aspect of the invention relates to a compound of the formula (AI) or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture thereof Or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, for use in the preparation of a prophylactic and/or therapeutic cardio-cerebral vascular disease, wherein the cardiovascular disease is preferably a thromboembolic disease, more preferably a myocardial infarction Re-occlusion and restenosis after angina pectoris, angioplasty or aortic coronary shunt, disseminated intravascular coagulation, stroke, transient ischemic attack, peripheral arterial occlusive disease, pulmonary embolism or deep vein thrombosis.
- the cardiovascular disease is preferably a thromboembolic disease, more preferably a myocardial infarction Re-occlusion and restenosis after angina pectoris, angioplasty or
- Another aspect of the invention relates to a method of preventing and/or treating a XIa factor mediated disease comprising administering to a patient a therapeutically effective amount of a compound of the formula (AI) or a tautomer thereof, A racemate, a racemate, an enantiomer, a diastereomer or a mixture thereof or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same.
- a compound of the formula (AI) or a tautomer thereof A racemate, a racemate, an enantiomer, a diastereomer or a mixture thereof or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same.
- Another aspect of the invention relates to a method for the treatment of prevention and/or treatment of cardiovascular and cerebrovascular diseases, comprising administering to a patient a therapeutically effective amount of a compound of the formula (AI) or a tautomer thereof, internal elimination a rotator, a racemate, an enantiomer, a diastereomer or a mixture thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, wherein the cardiovascular and cerebrovascular disease is selected from the group consisting of myocardial infarction Re-obstruction and restenosis, stroke, transient ischemic attack, peripheral arterial occlusive disease, pulmonary embolism, or deep vein thrombosis after angina pectoris, angioplasty, or aortic coronary shunt.
- a compound of the formula (AI) or a tautomer thereof internal elimination a rotator, a racemate, an enantiomer, a diastereomer or a mixture thereof,
- Another aspect of the invention relates to a medicament for inhibiting factor XIa, which comprises a compound of the formula (AI) or a tautomer thereof, a mesogen, a racemate, an enantiomer a form, a diastereomer or a mixture thereof or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same.
- a compound of the formula (AI) or a tautomer thereof a mesogen, a racemate, an enantiomer a form, a diastereomer or a mixture thereof or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same.
- the active ingredient-containing pharmaceutical composition may be in a form suitable for oral administration, such as tablets, dragees, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or Tincture.
- Oral compositions can be prepared according to any method known in the art for preparing pharmaceutical compositions, such compositions may contain one or more ingredients selected from the group consisting of sweeteners, flavoring agents, coloring agents, and preservatives, To provide a pleasing and tasty pharmaceutical preparation. Tablet containing the active ingredient and a non-toxic pharmaceutically acceptable tablet for mixing Excipients used.
- excipients can be inert excipients, granulating agents, disintegrating agents, binders, and lubricants. These tablets may be uncoated or may be coated by masking the taste of the drug or delaying disintegration and absorption in the gastrointestinal tract, thus providing a sustained release effect over a longer period of time.
- Oral formulations can also be provided in soft gelatine capsules in which the active ingredient is mixed with an inert solid diluent or the active ingredient in admixture with a water-soluble vehicle or an oil vehicle.
- the aqueous suspension contains the active substance and excipients suitable for the preparation of the aqueous suspension for mixing. Such excipients are suspending, dispersing or wetting agents.
- the aqueous suspensions may also contain one or more preservatives, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents.
- the oil suspension can be formulated by suspending the active ingredient in vegetable oil, or mineral oil.
- the oil suspension may contain a thickening agent.
- the above sweeteners and flavoring agents may be added to provide a palatable preparation. These compositions can be preserved by the addition of an antioxidant.
- the dispersible powders and granules suitable for the preparation of aqueous suspensions can be provided by the addition of water to provide the active ingredient and dispersing or wetting agents, suspending agents or one or more preservatives. Suitable dispersing or wetting agents and suspending agents can be used to illustrate the above examples. Other excipients such as sweetening, flavoring, and coloring agents may also be added. These compositions are preserved by the addition of an anti-oxidant such as ascorbic acid.
- compositions of the invention may also be in the form of an oil-in-water emulsion.
- the oil phase can be a vegetable oil, or a mineral oil or a mixture thereof.
- Suitable emulsifiers can be naturally occurring phospholipids, and emulsions can also contain sweeteners, flavoring agents, preservatives, and antioxidants.
- Such formulations may also contain a demulcent, a preservative, a colorant, and an antioxidant.
- the pharmaceutical compositions of the invention may be in the form of a sterile injectable aqueous solution.
- acceptable vehicles or solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
- the sterile injectable preparation may be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in the oily phase.
- the injection or microemulsion is injected into the bloodstream of the patient by topical injection.
- the solution and microemulsion are preferably administered in a manner that maintains a constant circulating concentration of the compound of the invention.
- a continuous intravenous delivery device can be used.
- An example of such a device is the Deltec CADD-PLUS.TM.5400 intravenous pump.
- compositions of the invention may be in the form of a sterile injectable aqueous or oily suspension for intramuscular and subcutaneous administration.
- the suspension may be formulated according to known techniques using those suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution or suspension prepared in a parenterally acceptable non-toxic diluent or solvent.
- sterile fixed oils may conveniently be employed as a solvent or suspension medium. Any blended fixed oil can be used for this purpose.
- fatty acids can also be prepared as injections.
- the compounds of the invention may be administered in the form of a suppository for rectal administration.
- These pharmaceutical compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid in the rectum and thus dissolves in the rectum to release the drug.
- the dosage of the drug to be administered depends on a variety of factors including, but not limited to, the following factors: the activity of the particular compound used, the age of the patient, the weight of the patient, the health of the patient, the behavior of the patient. , patient's diet, time of administration, mode of administration, rate of excretion, drug Combinations and the like; in addition, the optimal treatment mode such as the mode of treatment, the daily dose of the compound of the formula (I) or the kind of the pharmaceutically acceptable salt can be verified according to a conventional treatment regimen.
- alkyl refers to a saturated aliphatic hydrocarbon group which is a straight or branched chain group containing from 1 to 20 carbon atoms, preferably an alkyl group having from 1 to 12 carbon atoms, more preferably from 1 to 6 carbons.
- the alkyl group of the atom is a saturated aliphatic hydrocarbon group which is a straight or branched chain group containing from 1 to 20 carbon atoms, preferably an alkyl group having from 1 to 12 carbon atoms, more preferably from 1 to 6 carbons.
- Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1 ,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2- Methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3 - dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2 -methylhexyl, 3-methylhexyl, 4-methylhexyl,
- lower alkyl groups having from 1 to 6 carbon atoms, non-limiting examples including methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl Base, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethyl Butyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl Base, 2,3-dimethylbutyl and the like.
- the alkyl group may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available point of attachment, preferably one or more of the following groups, independently selected from hydrazine.
- alkylene refers to a saturated straight or branched aliphatic hydrocarbon radical having two residues derived from the removal of two hydrogen atoms from the same carbon atom of the parent alkane or two different carbon atoms.
- Non-limiting examples of alkylene include, but are not limited to, methylene (-CH 2 -), 1,1-ethylene (-CH(CH 3 )-), 1,2-ethylene (-CH 2 ) CH 2 )-, 1,1-propylene (-CH(CH 2 CH 3 )-), 1,2-propylene (-CH 2 CH(CH 3 )-), 1,3-propylene (-CH 2 CH 2 CH 2 -), 1,4-butylene (-CH 2 CH 2 CH 2 CH 2 -), and the like.
- the alkylene group may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available point of attachment, which is preferably independently independently selected from the group consisting of a ruthenium atom, an alkyl group, and an alkenyl group.
- cycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, -C(O)R 8 , -C(O)OR 8 and -S(O) m R 8 Substituted by a substituent.
- cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing from 3 to 20 carbon atoms, preferably from 3 to 12 carbon atoms, more preferably from 3 to 8 carbon atoms. One carbon atom, most preferably containing from 3 to 5 carbon atoms.
- Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene
- a cycloalkyl group or the like is preferably a cycloalkyl group;
- a polycyclic cycloalkyl group includes a spiro ring, a fused ring, and a bridged cycloalkyl group.
- spirocycloalkyl refers to a polycyclic group that shares a carbon atom (referred to as a spiro atom) between 5 to 20 members of a single ring, which may contain one or more double bonds, but none of the rings have a fully conjugated ⁇ electronic system. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- the spirocycloalkyl group is classified into a monospirocycloalkyl group, a bispirocycloalkyl group or a polyspirocycloalkyl group, preferably a monospirocycloalkyl group and a bispirocycloalkyl group, depending on the number of common spiro atoms between the rings.
- spirocycloalkyl groups include:
- fused cycloalkyl refers to 5 to 20 members, and each ring in the system shares an all-carbon polycyclic group of an adjacent pair of carbon atoms with other rings in the system, wherein one or more of the rings may contain one or Multiple double bonds, but none of the rings have a fully conjugated ⁇ -electron system. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- fused cycloalkyl groups include:
- bridged cycloalkyl refers to an all-carbon polycyclic group of 5 to 20 members, any two rings sharing two carbon atoms which are not directly bonded, which may contain one or more double bonds, but none of the rings have complete Conjugate ⁇ -electron system. It is preferably 6 to 14 members, more preferably 7 to 10 members. Depending on the number of constituent rings, it may be classified into a bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl group, preferably a bicyclic ring, a tricyclic ring or a tetracyclic ring, and more preferably a bicyclic ring or a tricyclic ring.
- bridged cycloalkyl groups include:
- the cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring to which the parent structure is attached is a cycloalkyl group, non-limiting examples include indanyl, tetrahydronaphthalene A benzocycloheptyl group or the like; preferably a phenylcyclopentyl group or a tetrahydronaphthyl group.
- the cycloalkyl group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio Substituted by one or more substituents of a heterocycloalkylthio group, an oxo group, -C(O)R 8 , -C(O)OR 8 and -S(O) m R 8 .
- heterocyclyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing from 3 to 20 ring atoms wherein one or more ring atoms are selected from nitrogen, oxygen or S(O).
- a hetero atom of m (where m is an integer of 0 to 2), but excluding the ring moiety of -OO-, -OS- or -SS-, the remaining ring atoms being carbon.
- Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, dihydroimidazolyl, dihydrofuranyl, m-dioxole , dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl and the like.
- Polycyclic heterocyclic groups include spiro, fused, and bridged heterocyclic groups.
- spiroheterocyclyl refers to a polycyclic heterocyclic group in which one atom (called a spiro atom) is shared between 5 to 20 members of a single ring, wherein one or more ring atoms are selected from nitrogen, oxygen or S (O). ) m (where m is an integer 0 to 2) heteroatoms, and the remaining ring atoms are carbon. It may contain one or more double bonds, but none of the rings have a fully conjugated pi-electron system. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- the spiroheterocyclyl group is classified into a monospiroheterocyclic group, a dispiroheterocyclic group or a polyspirocyclic group according to the number of shared spiro atoms between the ring and the ring, and is preferably a monospiroheterocyclic group and a dispiroheterocyclic group. More preferably, it is 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6-membered monospiroheterocyclic group.
- Non-limiting examples of spiroheterocyclyl groups include:
- fused heterocyclyl refers to 5 to 20 members, and each ring in the system shares an adjacent pair of atomic polycyclic heterocyclic groups with other rings in the system, and one or more rings may contain one or more Double bond, but none of the rings have a fully conjugated ⁇ -electron system in which one or more ring atoms are heteroatoms selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2), and the remaining rings
- the atom is carbon. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- fused heterocyclic groups include:
- bridge heterocyclyl refers to a polycyclic heterocyclic group of 5 to 14 members, any two rings sharing two atoms which are not directly bonded, which may contain one or more double bonds, but none of the rings have a total A ⁇ -electron system of a yoke in which one or more ring atoms are heteroatoms selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2), the remaining ring atoms being carbon. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- bridge heterocyclic groups include:
- the heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring to which the parent structure is attached is a heterocyclic group, non-limiting examples of which include:
- the heterocyclic group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio Substituted by one or more substituents of a heterocycloalkylthio group, an oxo group, -C(O)R 8 , -C(O)OR 8 and -S(O) m R 8 .
- aryl refers to a 6 to 20 membered all-carbon monocyclic or fused polycyclic ring (i.e., a ring sharing a pair of adjacent carbon atoms) having a conjugated ⁇ -electron system, preferably 6 to 10 members, more preferably 6 yuan, such as phenyl and naphthyl.
- the aryl ring may be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring to which the parent structure is attached is an aryl ring, non-limiting examples of which include:
- the aryl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of a halogen atom, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, and an alkane group.
- heteroaryl refers to a heteroaromatic system containing from 1 to 4 heteroatoms, from 5 to 20 ring atoms, wherein the heteroatoms are selected from the group consisting of oxygen, sulfur and nitrogen.
- the heteroaryl group is preferably 5 to 10 members, and has 1 to 3 hetero atoms; more preferably 5 or 6 members, and 1 to 2 hetero atoms; preferably, for example, imidazolyl, furyl, thienyl, thiazolyl, pyridyl Azolyl, oxazolyl, pyrrolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazole, pyrazinyl and the like.
- the heteroaryl ring may be fused to an aryl, heterocyclic or cycloalkyl ring, wherein the ring to which the parent structure is attached is a heteroaryl ring, non-limiting examples of which include:
- the heteroaryl group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio Substituted by one or more substituents of a heterocycloalkylthio group, -C(O)R 8 , -C(O)OR 8 and -S(O) m R 8 .
- alkoxy refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), wherein alkyl is as defined above.
- alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy.
- the alkoxy group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio Substituted by one or more substituents of a heterocycloalkylthio group, -C(O)R 8 , -C(O)OR 8 and -S(O) m R 8 .
- alkylthio refers to -S-(alkyl) and -S-(unsubstituted cycloalkyl), wherein alkyl is as defined above.
- alkylthio groups include: methylthio, ethylthio, propylthio, butylthio, cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio.
- the alkylthio group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane.
- cycloalkyloxy refers to -O-cycloalkyl, wherein cycloalkyl is as defined above.
- haloalkyl refers to an alkyl group substituted by a halogen wherein alkyl is as defined above.
- haloalkoxy refers to an alkoxy group substituted by a halogen wherein alkoxy is as defined above.
- hydroxyalkyl refers to an alkyl group substituted with a hydroxy group, wherein alkyl is as defined above.
- hydroxy refers to an -OH group.
- halogen means fluoro, chloro, bromo or iodo.
- amino means -NH 2.
- cyano refers to -CN.
- nitro refers to -NO 2 .
- carboxylate group refers to -C(O)O(alkyl) or -C(O)O(cycloalkyl), wherein alkyl, cycloalkyl are as defined above.
- heterocyclic group optionally substituted by an alkyl group means that an alkyl group may be, but not necessarily, present, and the description includes the case where the heterocyclic group is substituted with an alkyl group and the case where the heterocyclic group is not substituted with an alkyl group.
- Substituted refers to one or more hydrogen atoms in the group, preferably up to 5, more preferably 1 to 3, hydrogen atoms, independently of each other, substituted by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art will be able to determine without much effort (by experimentation). Or theory) may or may not be replaced. For example, an amino group or a hydroxyl group having a free hydrogen may be unstable when combined with a carbon atom having an unsaturated (e.g., olefinic) bond.
- “Pharmaceutical composition” means a mixture comprising one or more of the compounds described herein, or a physiologically/pharmaceutically acceptable salt or prodrug thereof, and other chemical components, as well as other components such as physiological/pharmaceutically acceptable carriers. And excipients.
- the purpose of the pharmaceutical composition is to promote the administration of the organism, which facilitates the absorption of the active ingredient and thereby exerts biological activity.
- “Pharmaceutically acceptable salt” refers to a salt of a compound of the invention which is safe and effective for use in a mammal and which possesses the desired biological activity.
- R 8 and m are as defined by the formula (AI).
- the first step is a reaction of a compound of the formula (AI-1) with a compound of the formula (AI-2) under basic conditions in an organic solvent to obtain a compound of the formula (AI-3); or a formula (AI) -1) the compound is subjected to nucleophilic substitution reaction with a general formula (AI-2') in an organic solvent under basic conditions to obtain a compound of the formula (AI-A);
- the second step reaction is a compound of the general formula (AI-3), which is hydrolyzed under acidic conditions to obtain a formula (AI-A);
- the compound of the formula (AI-A) and the compound of the formula (AI-B) or a hydrochloride thereof are subjected to a condensation reaction under basic conditions, optionally under basic conditions, to obtain a pass.
- a compound of formula (AI) is subjected to a condensation reaction under basic conditions, optionally under basic conditions, to obtain a pass.
- the reagents providing basic conditions include organic bases including, but not limited to, triethylamine, N,N-diisopropylethylamine, n-butyllithium, lithium diisopropylamide, and inorganic bases. , bis-trimethylsilylamino lithium, potassium acetate, sodium t-butoxide or potassium t-butoxide, said inorganic bases including but not limited to sodium hydride, potassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, hydrogen Sodium oxide and lithium hydroxide.
- Conditions which provide acidity include, but are not limited to, pyridine hydrobromide, trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid or methanesulfonic acid, preferably pyridine hydrobromide or hydrochloric acid.
- the condensing agent includes, but is not limited to, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N'-dicyclohexylcarbodiimide, N,N'- Diisopropylcarbodiimide, O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate, 1-hydroxybenzotriazole, 1-hydroxy- 7-azobenzotriazole, O-benzotriazole-N,N,N',N'-tetramethyluron hexafluorophosphate, 2-(7-oxobenzotriazole)-N ,N,N',N'-tetramethylurea hexafluorophosphate, 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluron hexafluorophosphate , benzotriazol-1-
- the above reaction is preferably carried out in a solvent including, but not limited to, acetic acid, methanol, ethanol, toluene, tetrahydrofuran, dichloromethane, dimethyl sulfoxide, 1,4-dioxane, water or N,N- dimethylformamide.
- a solvent including, but not limited to, acetic acid, methanol, ethanol, toluene, tetrahydrofuran, dichloromethane, dimethyl sulfoxide, 1,4-dioxane, water or N,N- dimethylformamide.
- X is a halogen, preferably bromine
- R a is an alkyl group, preferably a methyl group
- Ring A, R 1 to R 5 , n and s are as defined in the formula (AI).
- the first step is a compound of the formula (I-1) which is subjected to nucleophilic substitution reaction with (I-2) under basic conditions in an organic solvent to obtain a compound of the formula (I-3); or a compound of the formula (I-1).
- the nucleophilic substitution reaction with the general formula (I-2') under basic conditions in an organic solvent gives a compound of the formula (I-A);
- the second step reaction is a compound of the formula (I-3), which is hydrolyzed under acidic conditions to obtain a formula (I-A);
- the compound of the formula (IA) and the compound of (AI-B) or a hydrochloride thereof are subjected to a condensation reaction under basic conditions, optionally under basic conditions, to give a compound of the formula (I). ;
- the reagents providing basic conditions include organic bases including, but not limited to, triethylamine, N,N-diisopropylethylamine, n-butyllithium, lithium diisopropylamide, and inorganic bases. , bis-trimethylsilylamino lithium, potassium acetate, sodium t-butoxide or potassium t-butoxide, said inorganic bases including but not limited to sodium hydride, potassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, hydrogen Sodium oxide and lithium hydroxide.
- Conditions which provide acidity include, but are not limited to, pyridine hydrobromide, trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid or methanesulfonic acid, preferably pyridine hydrobromide or hydrochloric acid.
- Condensing agents include, but are not limited to, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N'-dicyclohexylcarbodiimide, N,N'-di Propylcarbodiimide, O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate, 1-hydroxybenzotriazole, 1-hydroxy-7- Azobenzotriazole, O-benzotriazole-N,N,N',N'-tetramethyluron hexafluorophosphate, 2-(7-oxobenzotriazole)-N,N , N', N'-tetramethylurea hexafluorophosphate, 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate, benzene And triazol-1-
- the above reaction is preferably carried out in a solvent including, but not limited to, acetic acid, methanol, ethanol, toluene, tetrahydrofuran, dichloromethane, dimethyl sulfoxide, 1,4-dioxane, water or N,N- dimethylformamide.
- a solvent including, but not limited to, acetic acid, methanol, ethanol, toluene, tetrahydrofuran, dichloromethane, dimethyl sulfoxide, 1,4-dioxane, water or N,N- dimethylformamide.
- X is a halogen, preferably bromine
- R a is an alkyl group, preferably a methyl group
- Rings A, L 1 , R 1 to R 3 , R 5 to R 6 , n and s are as defined in the formula (I).
- the first step of the reaction is a compound of the formula (I-1-a) in an organic solvent, and nucleophilic substitution reaction with (I-2-a) under basic conditions to obtain a compound of the formula (I-3);
- the second step reaction is a compound of the formula (I-3), which is hydrolyzed under acidic conditions to obtain a formula (I-A);
- the compound of the formula (IA) and the compound of (AI-B) or a hydrochloride thereof are subjected to a condensation reaction under basic conditions, optionally under basic conditions, to give a compound of the formula (I). ;
- the reagents providing basic conditions include organic bases including, but not limited to, triethylamine, N,N-diisopropylethylamine, n-butyllithium, lithium diisopropylamide, and inorganic bases. , bis-trimethylsilylamino lithium, potassium acetate, sodium t-butoxide or potassium t-butoxide, said inorganic bases including but not limited to sodium hydride, potassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, hydrogen Sodium oxide and lithium hydroxide.
- Conditions which provide acidity include, but are not limited to, pyridine hydrobromide, trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid or methanesulfonic acid, preferably pyridine hydrobromide or hydrochloric acid.
- Condensing agents include, but are not limited to, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N'-dicyclohexylcarbodiimide, N,N'-di Propylcarbodiimide, O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate, 1-hydroxybenzotriazole, 1-hydroxy-7- Azobenzotriazole, O-benzotriazole-N,N,N',N'-tetramethyluron hexafluorophosphate, 2-(7-oxobenzotriazole)-N,N , N', N'-tetramethylurea hexafluorophosphate, 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate, benzene Triazol-1-y
- the above reaction is preferably carried out in a solvent including, but not limited to, acetic acid, methanol, ethanol, toluene, tetrahydrofuran, dichloromethane, dimethyl sulfoxide, 1,4-dioxane, water or N,N- dimethylformamide.
- a solvent including, but not limited to, acetic acid, methanol, ethanol, toluene, tetrahydrofuran, dichloromethane, dimethyl sulfoxide, 1,4-dioxane, water or N,N- dimethylformamide.
- R a is an alkyl group, preferably a methyl group
- R b is a leaving group, preferably methanesulfonyloxy or trifluoromethanesulfonyloxy;
- Rings A, L 1 , R 1 to R 3 , R 5 to R 6 , n and s are as defined in the formula (I).
- the first step is a compound of the formula (II-1) which is subjected to nucleophilic substitution reaction with (I-2) under basic conditions in an organic solvent to obtain a compound of the formula (II-2); or a compound of the formula (II-1).
- the nucleophilic substitution reaction with the general formula (I-2') under basic conditions in an organic solvent gives a compound of the formula (II-A);
- the second step is a reaction of the compound of the formula (II-2) under acidic conditions to obtain the formula (II-A);
- the compound of the formula (II-A) and the compound of the formula (II-B) or a hydrochloride thereof are subjected to a condensation reaction under basic conditions, optionally under basic conditions, to obtain a formula (II).
- a condensation reaction under basic conditions, optionally under basic conditions, to obtain a formula (II).
- the reagents providing basic conditions include organic bases including, but not limited to, triethylamine, N,N-diisopropylethylamine, n-butyllithium, lithium diisopropylamide, and inorganic bases. , bis-trimethylsilylamino lithium, potassium acetate, sodium t-butoxide or potassium t-butoxide, preferably lithium bis trimethylsilylamine, said inorganic base package
- organic bases including, but not limited to, triethylamine, N,N-diisopropylethylamine, n-butyllithium, lithium diisopropylamide, and inorganic bases.
- bis-trimethylsilylamino lithium, potassium acetate, sodium t-butoxide or potassium t-butoxide preferably lithium bis trimethylsilylamine
- said inorganic base package include, but are not limited to, sodium hydride, potassium phosphate, sodium carbonate, potassium carbonate, cesium carbon
- Conditions which provide acidity include, but are not limited to, pyridine hydrobromide, trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid or methanesulfonic acid, preferably pyridine hydrobromide or hydrochloric acid.
- Condensing agents include, but are not limited to, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N'-dicyclohexylcarbodiimide, N,N'-di Propylcarbodiimide, O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate, 1-hydroxybenzotriazole, 1-hydroxy-7- Azobenzotriazole, O-benzotriazole-N,N,N',N'-tetramethyluron hexafluorophosphate, 2-(7-oxobenzotriazole)-N,N , N', N'-tetramethylurea hexafluorophosphate, 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate, benzene And triazol-1-
- the above reaction is preferably carried out in a solvent including, but not limited to, acetic acid, methanol, ethanol, toluene, tetrahydrofuran, dichloromethane, dimethyl sulfoxide, 1,4-dioxane, water or N,N- dimethylformamide.
- a solvent including, but not limited to, acetic acid, methanol, ethanol, toluene, tetrahydrofuran, dichloromethane, dimethyl sulfoxide, 1,4-dioxane, water or N,N- dimethylformamide.
- X is a halogen, preferably bromine
- R a is an alkyl group, preferably a methyl group
- L 1 , R 2 , R 3 , R 5 to R 7 and n are as defined in the formula (II);
- the first step is a compound of the formula (II-A) and a compound of the formula (IV-1) or a hydrochloride thereof is subjected to a condensation reaction under basic conditions to obtain a compound of the formula (IV-2);
- the second step is a reaction of the compound of the formula (IV-2) under acidic conditions to give a compound of the formula (IV-3);
- the third step is a chiral preparation of a compound of formula (IV-3) to give a compound of formula (IV);
- the reagents providing basic conditions include organic bases including, but not limited to, triethylamine, N,N-diisopropylethylamine, n-butyllithium, lithium diisopropylamide, and inorganic bases. , bis-trimethylsilylamino lithium, potassium acetate, sodium t-butoxide or potassium t-butoxide, preferably lithium bis trimethylsilylamine, said inorganic bases including but not limited to sodium hydride, phosphoric acid Potassium, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide or lithium hydroxide is preferably potassium carbonate, sodium hydride or lithium hydroxide.
- Conditions which provide acidity include, but are not limited to, pyridine hydrobromide, trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid or methanesulfonic acid, preferably pyridine hydrobromide or hydrochloric acid.
- Conditions for chiral preparation include, but are not limited to, the column being Superchiral S-AD (Chiralway), the mobile phase being carbon dioxide, ethanol and diethylamine.
- Condensing agents include, but are not limited to, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N'-dicyclohexylcarbodiimide, N,N'-di Propylcarbodiimide, O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate, 1-hydroxybenzotriazole, 1-hydroxy-7- Azobenzotriazole, O-benzotriazole-N,N,N',N'-tetramethyluron hexafluorophosphate, 2-(7-oxobenzotriazole)-N,N , N', N'-tetramethylurea hexafluorophosphate, 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate, benzene And triazol-1-
- the above reaction is preferably carried out in a solvent including, but not limited to, acetic acid, methanol, ethanol, toluene, tetrahydrofuran, dichloromethane, dimethyl sulfoxide, 1,4-dioxane, water or N,N- dimethylformamide.
- a solvent including, but not limited to, acetic acid, methanol, ethanol, toluene, tetrahydrofuran, dichloromethane, dimethyl sulfoxide, 1,4-dioxane, water or N,N- dimethylformamide.
- R c is an alkyl group, preferably a methyl group
- L 1 , R 2 , R 3 , R 6 , R 7 and n are as defined in the formula (IV).
- the compounds of the general formula involved in the present invention such as the form of the compound salt obtained during the synthesis, can be further obtained by conventional experimental means; if the free compound form is obtained during the synthesis, the compound can be further obtained by conventional experimental means. Salt.
- the structure of the compound is determined by nuclear magnetic resonance (NMR) or/and mass spectrometry (MS).
- NMR shift ( ⁇ ) is given in units of 10 -6 (ppm).
- NMR was measured using a Bruker AVANCE-400 nuclear magnetic apparatus, and the solvent was deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated chloroform (CDCl 3 ), deuterated methanol (CD 3 OD), internal standard was four.
- DMSO-d 6 dimethyl sulfoxide
- CDCl 3 deuterated chloroform
- CD 3 OD deuterated methanol
- TMS Methyl silane
- the measurement of the MS was carried out using a FINNIGAN LCQAd (ESI) mass spectrometer (manufacturer: Thermo, model: Finnigan LCQ advantage MAX).
- ESI FINNIGAN LCQAd
- HPLC High performance liquid chromatography
- Chiral HPLC analysis was performed using an Agilent 1260 DAD high performance liquid chromatograph.
- the CombiFlash Rapid Preparer uses the Combiflash Rf200 (TELEDYNE ISCO).
- Thin layer chromatography silica gel plate uses Yantai Yellow Sea HSGF254 or Qingdao GF254 silica gel plate.
- the specification of silica gel plate used for thin layer chromatography (TLC) is 0.15mm ⁇ 0.2mm.
- the specification for thin layer chromatography separation and purification is 0.4mm. ⁇ 0.5mm.
- Silica gel column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as a carrier.
- the known starting materials of the present invention may be synthesized by or according to methods known in the art, or may be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc, Companies such as Dare Chemicals.
- the reactions can all be carried out under an argon atmosphere or a nitrogen atmosphere.
- An argon atmosphere or a nitrogen atmosphere means that the reaction flask is connected to an argon or nitrogen balloon having a volume of about 1 L.
- the hydrogen atmosphere means that the reaction flask is connected to a hydrogen balloon of about 1 L volume.
- the pressurized hydrogenation reaction was carried out using a Parr Model 3916EKX hydrogenation apparatus and a clear blue QL-500 type hydrogen generator or a HC2-SS type hydrogenation apparatus.
- the hydrogenation reaction is usually evacuated, charged with hydrogen, and operated three times.
- the microwave reaction used a CEM Discover-S Model 908860 microwave reactor.
- the solution means an aqueous solution.
- reaction temperature is room temperature and is 20 ° C to 30 ° C.
- TLC thin layer chromatography
- the developing agent used for the reaction the column chromatography eluent system used for the purification of the compound
- the thin layer chromatography developing solvent system including: A: Methylene chloride/methanol system, B: n-hexane/ethyl acetate system, C: petroleum ether/ethyl acetate system, D: acetone, E: dichloromethane/acetone system, F: ethyl acetate/dichloromethane system , G: ethyl acetate / dichloromethane / n-hexane, H: ethyl acetate / dichloromethane / acetone, I: petroleum ether / ethyl acetate / dichloromethane, the volume ratio of the solvent is different depending on the polarity of the compound Adjustment can also be carried out by adding a small amount of an alkaline or acidic acidic acidic acidic acidic acidic acid
- Methyl 4-methoxybutyrate 1a (1.6 g, 12.1 mmol) was added to 50 mL of tetrahydrofuran, cooled to -78 ° C with a dry ice-acetone bath, and di-trimethylsilylamine lithium (12.7 mL, 12.7 mmol), after the addition was completed, the reaction was stirred for 1 hour, trimethylchlorosilane (1.31 g, 12.1 mmol) was added, and the reaction was further stirred for 20 minutes, and then N-bromosuccinimide (2.15 g, 12.1 mmol) was added. The reaction was stirred for 2 hours.
- reaction solution was naturally cooled to room temperature, and 50 mL of water was added to the reaction mixture, and the mixture was combined with ethyl acetate (50 mL ⁇ 3), and the organic phase was combined, and the organic phase was washed with water (50 mL) The organic layer was dried (MgSO4), evaporated, evaporated,
- 2-Bromo-4-chloro-1-iodobenzene 8a (1.0 g, 3.15 mmol, prepared by a known method "Angewandte Chemie, International Edition, 2010, 49 (46), 8729-8732”) was dissolved in 1 mL The mixture was cooled to -20 ° C in tetrahydrofuran, and isopropylmagnesium chloride (421.15 mg, 4.10 mmol) was added, and the mixture was reacted for 1 hour.
- Propionyl chloride 8b (378.89 mg, 4.10 mmol), lithium chloride (11.42 mg, 189.00 ⁇ mol), cuprous chloride (9.36 mg, 94.50 ⁇ mol) and aluminum trichloride (12.61 mg, 94.50 ⁇ mol) were added to 1 mL of tetrahydrofuran. The mixture was stirred at room temperature, and the reaction liquid which had been reacted for 1 hour in advance was added to the above mixture, and reacted at room temperature for 2 hours. The reaction mixture was quenched by the addition of 20 mL of EtOAc EtOAc (EtOAc) The obtained residue was purified to give the title compound 8c (640 mg, yield: 82.0%).
- reaction solution was cooled to room temperature, poured into 100 mL of ice-water, and then evaporated with ethyl acetate (60 mL ⁇ 3), and the organic phase was combined, washed with 25 mL of saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, The obtained residue was purified to silica gel elut372 elut elut elut elut elut elut
- Chiral HPLC analysis retention time 5.297 minutes, (column: CHIRAL PAK IE, 4.6*150 mm, 5 um; flow rate: 1 mL/min; mobile phase: ethanol).
- Chiral HPLC analysis retention time 8.442 minutes, (column: CHIRAL PAK IE, 4.6*150 mm, 5 um; flow rate: 1 mL/min; mobile phase: ethanol).
- the crude compound 16d (70 mg, 115.89 ⁇ mol) was dissolved in 8 mL of tetrahydrofuran, and platinum chloride (5.26 mg, 23.18 ⁇ mol) was added thereto, and the mixture was replaced with hydrogen twice, and the mixture was stirred at room temperature for 2.5 hours. The reaction mixture was filtered, and the filtrate was evaporated.
- the reaction was quenched by slowly adding 1 mL of water to the reaction mixture at -78 ° C, and the mixture was warmed to room temperature, then 10 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL ⁇ 2), and the organic phase was combined and washed with saturated sodium chloride solution (20 mL ⁇ 2) Dry with anhydrous sodium sulfate. Filtration, the filtrate was concentrated under reduced pressure.
- the compound 17f (200 mg, 0.297 mmol) was dissolved in a mixed solvent of 2 mL of methanol and 2 mL of tetrahydrofuran, and lithium hydroxide monohydrate (29.9 mg, 0.71 mmol) was added to the reaction mixture, and the reaction was stirred for 60 hours. 15 mL of water was added to the reaction mixture, and 3 M hydrochloric acid was added dropwise to pH 4 to 5, and extracted with ethyl acetate (20 mL ⁇ 2). The organic phase was combined and washed with saturated sodium chloride solution (20 mL ⁇ 2), anhydrous sodium sulfate Dry, filter, and concentrate the filtrate under reduced pressure. Purified by high-performance liquid chromatography (Waters 2767-SQ detecor 2, elution system: acetonitrile, water) The residue was obtained to give the title compound 17 (10 mg, yield: 16.2%).
- Example 23 Using the synthetic route of Example 23, the starting compound 23a was replaced with 4-aminobenzamide (prepared by a known method "Chemical Communications (Cambridge, United Kingdom), 2017, 53 (35), 4807-4810") The title compound 24 (150 mg) was obtained.
- Example 23 Using the synthetic route of Example 23, the starting compound 23a was replaced with 6-aminocarbazole (prepared by a known method "Tetrahedron Letters, 2010, 51 (5), 786-789") to give the title compound 27 ( 45mg).
- Example 18 Using the synthetic route of Example 18, the starting compound 18a was replaced with 6-amino-1H-indole-3-carbonitrile (prepared by the method disclosed in the patent application "WO 20160271105”) to obtain the title compound 28 (30 mg). ).
- Example 8 Using the synthetic route of Example 8, the starting compound 8c was replaced by 1-(2-bromo-4-chlorophenyl)-2,2,2-trifluoroethyl ketone (prepared by the method disclosed in the patent application "WO2011100285"). The title compound 35 (10 mg) was obtained.
- the title compound 37 (40 mg) was obtained from the title compound.
- Example 8 Using the synthetic route of Example 8, the starting compound 8b was replaced with cyclopropylacetyl chloride (prepared by the method disclosed in the patent application "WO 2015110435"), and the raw material cuprous chloride was replaced with cuprous iodide to obtain the title compound. 39 (30 mg).
- the title compound 40 (80 mg) was obtained from the title compound 40a.
- Example 8 Using the synthetic route of Example 8, the starting compound 8b was replaced with cyclopropanoyl chloride (prepared by the method disclosed in the patent application "WO 2015143380”) to give the title compound 41 (60 mg).
- Example 18 Using the synthetic route of Example 18, the starting compound 18a was replaced with 6-aminocarbazole (prepared by the known method "Tetrahedron Letters, 2010, 51 (5), 786-789") to give the title compound 42 ( 83mg).
- the title compound 43 (40 mg) was obtained from the title compound.
- Example 8 Using the synthetic route of Example 8, the starting compound 8b was replaced with isobutyryl chloride (prepared by the known method "Organic Letters, 2017, 19(7), 1768-1771") to give the title compound 44 (200 mg). .
- Example 48 Using the synthetic route of Example 48, the starting compound 48a was replaced with 2-methyl-1H-benzo[d]imidazole-5-amine (prepared by the method disclosed in the patent application "WO2012044090") to obtain the title compound. 49 (40 mg).
- the title compound 50 (40 mg) was obtained from the title compound.
- Example 38 Using the synthetic route of Example 38, the starting compound 38a was replaced with 6-amino-1H-indole-2-carbonitrile (prepared by the method disclosed in the patent application "WO20160271105”) to give the title compound 54 (30 mg). .
- Example 18 Using the synthetic route of Example 18, the starting compound 18a was replaced with 4-amino-2-(trifluoromethyl)benzonitrile (prepared by a known method "Medicinal Chemistry Research, 2016, 25(4), 539-552"). The title compound 55 (40 mg) was obtained.
- Example 18 Using the synthetic route of Example 18, the starting compound 18a was replaced with 4-(aminosulfonyl)aniline (prepared by a known method "Journal of Organic Chemistry, 2014, 79 (19), 9433-9439”). The title compound 58 (40 mg) was obtained.
- Example 18 Using the synthetic route of Example 18, the starting compound 18a was replaced with 4-amino-3-fluorobenzonitrile (prepared by the well-known method "Journal of Medicinal Chemistry, 2005, 48 (18), 5823-5836"), The title compound 59 (20 mg) was obtained.
- Example 18 Using the synthetic route of Example 18, the starting compound 18a was replaced with 6-amino-2H-benzo[b][1,4]oxazin-3(4H)-one (prepared by the method disclosed in the patent application "WO20100216783"). The title compound 60 (50 mg) was obtained.
- Example 4 Using the synthetic route of Example 4, the starting compound 4a was replaced with 2-bromo-3-(4-fluorophenyl)propionic acid (prepared by the method disclosed in the patent application "US5981529A") to give the title compound 63 ( 64mg).
- Example 7 Using the synthetic route of Example 7, the starting compound 7c was replaced with 1-bromo-2-(bromomethyl)benzene (prepared by a known method "Bioorganic & Medicinal Chemistry Letters, 2014, 24(21), 5127-5133"). The title compound 64 (8 mg) was obtained.
- Example 7 Using the synthetic route of Example 7, the starting compound 7c was replaced with 1-(bromomethyl)-2-methylbenzene (prepared by a known method "Journal of Organic Chemistry, 2014, 79(1), 223-229”). The title compound 66 (60 mg) was obtained.
- the starting compound 7c was replaced with 1-(bromomethyl)-3-methylbenzene by the synthetic route of Example 7 (using a known method "Chemical Communications (Cambridge, United Kingdom), 2014, 50 (28), 3692
- the title compound 67 (80 mg) was obtained.
- Example 7 Using the synthetic route of Example 7, the starting compound 7c was replaced by 1-(bromomethyl)-2-fluorobenzene (prepared by the known method "Tetrahedron Letters, 2000, 41 (27), 5161-5164") The title compound 68 (55 mg) was obtained.
- Example 4 Using the synthetic route of Example 4, the starting compound 4a was replaced with 2-bromo-3-(4-chlorophenyl)propionic acid (prepared by the method disclosed in the patent application "WO2012118216") to obtain the title compound 69 ( 15mg).
- Example 7 Using the synthetic route of Example 7, the starting compound 7c was replaced by 1-(bromomethyl)-2-chlorobenzene (prepared by the known method "Tetrahedron Letters, 2016, 57(2), 168-171") The title compound 70 (25 mg) was obtained.
- Example 7 Using the synthetic route of Example 7, the starting compound 7c was replaced with 1-(bromomethyl)-3-methoxybenzene (prepared by the method disclosed in the patent application "WO2014135095") to give the title compound 71 (48 mg). ).
- Example 74 Using the synthetic route of Example 74, the starting compound 74a was replaced with 2-(bromomethyl)-1,3-dichlorobenzene (prepared by the known method "Organic Letters, 2017, 19(7), 1634-1637". The title compound 76 (20 mg) was obtained.
- Example 74 Using the synthetic route of Example 74, the starting compound 74a was replaced with 1-(bromomethyl)-2-methoxybenzene (using a known method "Journal of the American Chemical Society, 2013, 135(30), 10934- The title compound 78 (60 mg) was obtained.
- Example 74 Using the synthetic route of Example 74, the starting compound 74a was replaced with 2-(bromomethyl)pyridine (prepared by the well-known method "Journal of the American Chemical Society, 2016, 138(26), 8253-8258"). The title compound 79 (370 mg) was obtained.
- Example 74 Using the synthetic route of Example 74, the starting compound 74a was replaced with 3-(bromomethyl)pyridine (prepared by the known method "Chemical Communications (Cambridge, United Kingdom), 2016, 52(82), 12159-12162”). The title compound 82 (30 mg) was obtained.
- Example 74 Using the synthetic route of Example 74, the starting compound 74a was replaced with 4-(bromomethyl)pyridine hydrobromide (using a known method "Chemical Communications (Cambridge, United Kingdom), 2011, 47(5), 1482- The title compound 86 (20 mg) was obtained.
- Example 7 Using the synthetic route of Example 7, the starting compound 7c was replaced by 2-(bromomethyl)benzonitrile (known in the art) The title compound (manufactured by Journal of Organic Chemistry, 2014, 79(23), 11592-11608) was prepared to give the title compound 87 (15 mg).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
化合物编号 | IC50(FXIa)/(nM) |
1 | 34 |
2 | 19 |
3 | 1741 |
4 | 39 |
5 | 16 |
6 | 1817 |
7 | 34 |
8 | 17 |
9 | 14 |
11 | 13 |
12 | 42 |
13 | 46 |
16 | 100 |
18 | 56 |
19 | 5690 |
20 | 36 |
21 | 36 |
23 | 24 |
24 | 36 |
25 | 1523 |
26 | 21 |
27 | 66 |
29 | 90 |
37 | 29 |
38 | 30 |
39 | 38 |
40 | 38 |
41 | 39 |
42 | 40 |
43 | 47 |
44 | 53 |
45 | 69 |
46 | 71 |
47 | 82 |
63 | 55 |
64 | 58 |
65 | 43 |
66 | 34 |
67 | 35 |
68 | 47 |
69 | 49 |
70 | 54 |
71 | 46 |
72 | 21 |
74 | 100 |
75 | 100 |
76 | 100 |
78 | 72 |
79 | 45 |
80 | 40 |
81 | 2678 |
82 | 68 |
83 | >10000 |
84 | 42 |
85 | 92 |
86 | 99 |
87 | 73 |
88 | 74 |
89 | 42 |
90 | 100 |
91 | 50 |
92 | 21 |
93 | 42 |
94 | 24 |
95 | 7513 |
96 | 32 |
97 | 36 |
98 | 40 |
99 | 29 |
100 | 35 |
101 | 23 |
102 | 8213 |
103 | 70 |
104 | 8146 |
105 | 30 |
108 | 12 |
109 | 5456 |
110 | 53 |
111 | 18 |
112 | >10000 |
113 | 33 |
114 | 27 |
115 | >10000 |
119 | 45 |
120 | 49 |
121 | 67 |
122 | 100 |
123 | 100 |
124 | 100 |
141 | 66 |
146 | 37 |
147 | 56 |
155 | 81 |
158 | 46 |
159 | 33 |
160 | 68 |
161 | 13110 |
162 | 35 |
163 | 9114 |
164 | 30 |
166 | 42 |
167 | 92 |
168 | 43 |
171 | 35 |
172 | 8918 |
173 | 100 |
176 | 71 |
177 | 27 |
178 | 7956 |
179 | 31 |
180 | 4834 |
化合物编号 | 抑制血小板凝集CT2(μM) |
1 | 4.4 |
2 | 2.9 |
3 | >10000 |
5 | 2.0 |
6 | >10000 |
8 | 6.4 |
9 | 2.4 |
11 | 4.2 |
13 | 6.0 |
20 | 6.5 |
31 | 8.5 |
37 | 7.8 |
39 | 8.3 |
80 | 7.9 |
81 | >10000 |
85 | 6.5 |
89 | 5.7 |
91 | 2.1 |
92 | 1.2 |
93 | 2.9 |
94 | 2.2 |
96 | 6.7 |
97 | 5.4 |
98 | 7.6 |
99 | 3.5 |
100 | 3.3 |
104 | >10000 |
105 | 6.9 |
108 | 1.4 |
109 | >10000 |
111 | 3.2 |
112 | >10000 |
114 | 3.6 |
160 | 3.8 |
163 | >10000 |
164 | 6.4 |
166 | 7.2 |
177 | 1.5 |
178 | >10000 |
179 | 3.3 |
180 | >10000 |
181 | 2.3 |
183 | 2.6 |
184 | >10000 |
化合物编号 | 抑制血小板凝集CT2(μM) |
114 | 2.9 |
对比例2 | 13.1 |
Claims (24)
- 一种通式(AI)所示的化合物:或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其可药用的盐、或其前药,其中:环A为芳基或杂芳基;R1为-C(O)R7;R2相同或不同,且各自独立地选自氢原子、卤素、烷基、卤代烷基、烷氧基、卤代烷氧基、氨基、硝基、氰基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基;R3选自卤素、烷基、卤代烷基、烷氧基、环烷基氧基、卤代烷氧基、氨基、硝基、氰基、羟基、羟烷基和烷硫基,其中所述的烷基、烷氧基、卤代烷基、卤代烷氧基、羟烷基和烷硫基任选进一步被选自氘原子、卤素、烷氧基、卤代烷氧基、氨基、硝基、氰基、羟基和羟烷基中的一个或多个取代基所取代;R4选自氢原子、烷基、烷氧基、卤代烷基、羟烷基、环烷基、环烷基氧基、杂环基、芳基和杂芳基,其中所述的烷基、环烷基、杂环基、芳基和杂芳基任选进一步被一个或多个R9取代基所取代;R5相同或不同,且各自独立地选自氢原子、烷基、烷氧基、氧代基、卤素、卤代烷基、卤代烷氧基、氨基、硝基、氰基、羟基、羟烷基、环烷基、杂环基、芳基、杂芳基、-C(O)R8、-C(O)OR8、-NHC(O)R8、-NHC(O)OR8、-NR10R11、-C(O)NR10R11、-CH2NHC(O)OR8、-CH2NR10R11、-C(O)OCH(R10)R11和-S(O)mR8,其中所述的烷基任选进一步被选自氘原子、卤素、烷氧基、卤代烷氧基、氨基、硝基、氰基、羟基、羟烷基、-NR10R11和-NHC(O)OR8中的一个或多个取代基所取代;;R7选自氢原子、烷基、卤代烷基、烷氧基、卤代烷氧基、氨基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基,其中所述的烷基、烷氧基、环烷基、杂环基、芳基和杂芳基任选进一步被选自氢原子、氘原子、卤素、烷基、烷氧基、卤代烷氧基、氨基、硝基、氰基、羟基、羟烷基、环烷基、环烷基氧基、杂环基、芳基和杂芳基中的一个或多个取代基所取代;R8选自氢原子、烷基、卤代烷基、羟基、氨基、环烷基、杂环基、芳基和杂芳基;R9选自氢原子、氘原子、卤素、烷基、烷氧基、卤代烷基、氨基、硝基、氰基、羟基、羟烷基、环烷基、环烷基氧基、杂环基、芳基和杂芳基,其中所述的环烷基、杂环基、芳基和杂芳基任选进一步被选自氘原子、卤素、烷基、烷氧基、卤代烷基、氨基、硝基、氰基、羟基、羟烷基、环烷基、环烷基氧基、杂环基、-NHC(O)R12和R13中的一个或多个取代基所取代;R10和R11相同或不同,且各自独立地选自氢原子、烷基、卤代烷基、环烷基、杂环基、-C(O)OR8和-OC(O)OR12,其中所述的环烷基和杂环基任选进一步被选自氘原子、卤素、烷基、烷氧基、卤代烷基、氧代基、氨基、硝基、氰基、羟基和羟烷基中的一个或多个取代基所取代;R12选自氢原子、烷基、烷氧基、卤代烷基、卤代烷氧基、氨基、环烷基、杂环基、芳基和杂芳基;R13为芳基或杂芳基,其中所述的芳基和杂芳基任选进一步被选自氢原子、氘原子、卤素、烷基、烷氧基、卤代烷基、氨基、硝基、氰基、羟基、羟烷基、环烷基、环烷基氧基和杂环基中的一个或多个取代基所取代;n为0、1、2、3或4;m为0、1或2;且s为0、1、2、3或4。
- 根据权利要求1所述的通式(AI)所示的化合物,其为通式(I)所示的化合物:或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体或其混合物形式,或其可药用的盐,其中:L1为亚烷基,其中所述的亚烷基任选进一步被卤素或氘原子中的一个或多个所取代;R6选自氢原子、氘原子、卤素、烷基、烷氧基、氨基、硝基、氰基、羟基、羟烷基、环烷基、环烷基氧基、杂环基、芳基和杂芳基,其中所述的环烷基、杂环基、芳基和杂芳基任选进一步被选自氘原子、卤素、烷基、烷氧基、卤代烷基、氨基、硝基、氰基、羟基、羟烷基、环烷基、环烷基氧基、杂环基、-NHC(O)R12 和R13中的一个或多个取代基所取代;R12选自氢原子、烷基、卤代烷基、氨基、环烷基、杂环基、芳基和杂芳基;R13为芳基或杂芳基,其中所述的芳基和杂芳基任选进一步被选自氢原子、氘原子、卤素、烷基、烷氧基、卤代烷基、氨基、硝基、氰基、羟基、羟烷基、环烷基、环烷基氧基和杂环基中的一个或多个取代基所取代;环A、R1~R3、R5、n和s如权利要求1中所定义。
- 根据权利要求1~5中任一项所述的通式(AI)所示的化合物,其中R5相同或不同,且各自独立地选自烷基、烷氧基、氧代基、卤素、卤代烷基、氰基、羟基、-C(O)OR8、-NHC(O)OR8、-C(O)NR10R11、-CH2NHC(O)OR8、-CH2NR10R11、-C(O)OCH(R10)R11和-S(O)mR8;R8选自氢原子、烷基、羟基和氨基;R10和R11相同或不同,且各自独立地选自氢原子、烷基、卤代烷基、环烷基、杂环基、-C(O)OR8和-OC(O)OR12,其中所述的环烷基和杂环基任选进一步被选自氘原子、卤素、烷基、烷氧基、卤代烷基、氧代基、氨基、硝基、氰基、羟基和羟烷基中的一个或多个取代基所取代;R12为烷基。
- 根据权利要求1~6中任一项所述的通式(AI)所示的化合物,其中R1为-C(O)R7;R7选自烷基、环烷基和卤代烷基,其中所述的烷基或环烷基任选进一步被选自氘原子、卤素、烷基和环烷基中的一个或多个取代基所取代。
- 根据权利要求1~7中任一项所述的通式(AI)所示的化合物,其为通式(III)所示的化合物:其中:R5相同或不同,且各自独立地选自烷基、烷氧基、氧代基、卤素、卤代烷基、氰基、羟基、-C(O)OR8、-NHC(O)OR8、-C(O)NR10R11、-CH2NHC(O)OR8、-CH2NR10R11、-C(O)OCH(R10)R11和-S(O)mR8;R8选自氢原子、烷基、羟基和氨基;R10和R11相同或不同,且各自独立地选自氢原子、烷基、卤代烷基、环烷基、杂环基、-C(O)OR8和-OC(O)OR12,其中所述的环烷基和杂环基任选进一步被选自氘原子、卤素、烷基、烷氧基、卤代烷基、氧代基、氨基、硝基、氰基、羟基和羟烷基中的一个或多个取代基所取代;R12为烷基;R7选自烷基、环烷基和卤代烷基,其中所述的烷基或环烷基任选进一步被选自氘原子、卤素、烷基和环烷基中的一个或多个取代基所取代;L1、R2、R3、R6和n如权利要求2中所定义。
- 根据权利要求1~9中任一项所述的通式(AI)所示的化合物,其中R2为卤素;n为0、1或2。
- 根据权利要求1~10中任一项所述的通式(AI)所示的化合物,其中R3为烷氧基,其中所述的烷氧基进一步任选被氘原子和卤素中的一个或多个所取代。
- 根据权利要求2~11中任一项所述的通式(I)所示的化合物,其中L1为-(CR14 2)x-,x为1~4的整数;R14为氢原子或氘原子;R6选自氢原子、氘原子、卤素、烷基、烷氧基、环烷基、环烷基氧基、杂环基、芳基和杂芳基;其中所述的环烷基、杂环基、芳基和杂芳基任选进一步被选自氘原子、卤素、烷基、烷氧基、环烷基、杂环基、-NHC(O)R12和R13中的一个或多个取代基所取代;R12为烷基或环烷基;R13为芳基或杂芳基,其中所述的芳基和杂芳基任选进一步被选自氘原子、卤素、烷基、烷氧基、卤代烷基、氨基、硝基、氰基和羟基中的一个或多个取代基所取代。
- 根据权利要求2~12中任一项所述的通式(I)所示的化合物,其中L1为-CH2-或-CD2-;R6选自环烷基、杂环基、芳基或杂芳基;其中所述的环烷基、杂环基、芳基和杂芳基任选进一步被选自氘原子、卤素、烷基、烷氧基、环烷基、杂环基、-NHC(O)R12和R13中的一个或多个取代基所取代;R12为烷基或环烷基;R13为芳基或杂芳基,其中所述的芳基和杂芳基任选进一步被选自氘原子、卤素、烷基、烷氧基、卤代烷基、氨基、硝基、氰基和羟基中的一个或多个取代基所取代。
- 根据权利要求2~12中任一项所述的通式(I)所示的化合物,其中L1为-CH2CH2-;R6为烷基、烷氧基或环烷基氧基。
- 一种药物组合物,其含有治疗有效量的根据权利要求1~15中任一项所述的通式(AI)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体或其混合物形式,或其可药用的盐以及药学上可接受的载体、稀释剂和赋形剂。
- 根据权利要求1~15任一项所述的通式(AI)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体或其混合物形式或其可药用的盐或根据权利要求18所述的药物组合物,在制备用于抑制XIa因子的药物中的用途。
- 根据权利要求1~15中任一项所述的通式(AI)所示的化合物或其互变异构体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其可药用的盐或根据权利要求18所述的药物组合物,其用作XIa抑制剂。
- 根据权利要求1~15任一项所述的通式(AI)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体或其混合物形式或其可药用的盐或根据权利要求18所述的药物组合物,在制备预防和/或治疗XIa因子介导的疾病的药物中的用途。
- 一种预防和/或治疗XIa因子介导的疾病的方法,其包括向患者施用治疗有效剂量的根据权利要求1~15任一项所述的通式(I)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体或其混合物形式或其可药用盐或根据权利要求18所述的药物组合物。
- 根据权利要求1~15任一项所述的通式(AI)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体或其混合物形式或其可药用的盐或根据权利要求18所述的药物组合物,在制备预防和/或治疗心脑血管疾病的药物中的用途,其中所述的心血管疾病,优选为血栓栓塞性疾病,更优选为心肌梗塞、心绞痛、血管成型术或主动脉冠状动脉分流术后的再阻塞和再狭窄、弥散性血管内凝血、中风、短暂的局部缺血发作、周围动脉闭塞性疾病、肺栓塞或深部静脉血栓形成。
- 一种预防和/或治疗心脑血管疾病的方法,其中所述的心血管疾病,优选为血栓栓塞性疾病,更优选为心肌梗塞、心绞痛、血管成型术或主动脉冠状动脉分流术后的再阻塞和再狭窄、弥散性血管内凝血、中风、短暂的局部缺血发作、周围动脉闭塞性疾病、肺栓塞或深部静脉血栓形成,其包括向患者施用治疗有效剂量的根据权利要求1~15任一项所述的通式(I)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体或其混合物形式或其可药用盐或根据权利要求18所述的药物组合物。
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2019107938A RU2742771C2 (ru) | 2016-08-31 | 2017-08-30 | Производное оксопиколинамида, способ его получения и его фармацевтическое применение |
CN202111196664.6A CN113929618B (zh) | 2016-08-31 | 2017-08-30 | 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用 |
UAA201902875A UA125520C2 (uk) | 2016-08-31 | 2017-08-30 | Похідні оксопіколінаміду, спосіб їх отримання та їх фармацевтичне застосування |
CA3031592A CA3031592A1 (en) | 2016-08-31 | 2017-08-30 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof |
AU2017317988A AU2017317988B2 (en) | 2016-08-31 | 2017-08-30 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof |
MX2019001481A MX2019001481A (es) | 2016-08-31 | 2017-08-30 | Derivado de oxopicolinamida, metodo de preparacion y uso farmaceutico del mismo. |
BR112019003557-5A BR112019003557A2 (pt) | 2016-08-31 | 2017-08-30 | derivados de oxopicolinamida, método de preparação dos mesmos e uso farmacêutico dos mesmos |
JP2019511336A JP7032814B2 (ja) | 2016-08-31 | 2017-08-30 | オキソピコリンアミド誘導体、その製造方法およびその医薬用途 |
PL17845424T PL3486242T3 (pl) | 2016-08-31 | 2017-08-30 | Pochodna oksopikolinamidu, sposób jej wytwarzania i zastosowanie farmaceutyczne |
DK17845424.5T DK3486242T3 (da) | 2016-08-31 | 2017-08-30 | Oxopicolinamidderivat, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf |
CN201780004214.8A CN108495850B (zh) | 2016-08-31 | 2017-08-30 | 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用 |
ES17845424T ES2903283T3 (es) | 2016-08-31 | 2017-08-30 | Derivado de oxipicolinamida, método de preparación y uso farmacéutico del mismo |
US16/328,128 US10633375B2 (en) | 2016-08-31 | 2017-08-30 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof |
CN202111197415.9A CN113912586B (zh) | 2016-08-31 | 2017-08-30 | 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用 |
EP17845424.5A EP3486242B1 (en) | 2016-08-31 | 2017-08-30 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof |
KR1020197007965A KR102416718B1 (ko) | 2016-08-31 | 2017-08-30 | 옥소피콜린아미드 유도체, 이에 대한 제조 방법 및 이의 약학적 용도 |
HK18114604.9A HK1255566A1 (zh) | 2016-08-31 | 2018-11-15 | 氧代吡啶酰胺類衍生物、其製備方法及其在醫藥上的應用 |
US16/804,180 US11084808B2 (en) | 2016-08-31 | 2020-02-28 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610789384 | 2016-08-31 | ||
CN201610789384.9 | 2016-08-31 | ||
CN201710014133.8 | 2017-01-09 | ||
CN201710014133 | 2017-01-09 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/328,128 A-371-Of-International US10633375B2 (en) | 2016-08-31 | 2017-08-30 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof |
US16/804,180 Continuation US11084808B2 (en) | 2016-08-31 | 2020-02-28 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018041122A1 true WO2018041122A1 (zh) | 2018-03-08 |
Family
ID=61300096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/099579 WO2018041122A1 (zh) | 2016-08-31 | 2017-08-30 | 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用 |
Country Status (19)
Country | Link |
---|---|
US (2) | US10633375B2 (zh) |
EP (1) | EP3486242B1 (zh) |
JP (1) | JP7032814B2 (zh) |
KR (1) | KR102416718B1 (zh) |
CN (3) | CN113929618B (zh) |
AU (1) | AU2017317988B2 (zh) |
BR (1) | BR112019003557A2 (zh) |
CA (1) | CA3031592A1 (zh) |
DK (1) | DK3486242T3 (zh) |
ES (1) | ES2903283T3 (zh) |
HK (1) | HK1255566A1 (zh) |
HU (1) | HUE057289T2 (zh) |
MX (1) | MX2019001481A (zh) |
PL (1) | PL3486242T3 (zh) |
PT (1) | PT3486242T (zh) |
RU (1) | RU2742771C2 (zh) |
TW (1) | TWI756257B (zh) |
UA (1) | UA125520C2 (zh) |
WO (1) | WO2018041122A1 (zh) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019197244A1 (en) | 2018-04-10 | 2019-10-17 | Bayer Pharma Aktiengesellschaft | A substituted oxopyridine derivative |
WO2020007256A1 (zh) * | 2018-07-02 | 2020-01-09 | 江苏恒瑞医药股份有限公司 | 一种氧代吡啶酰胺类衍生物的晶型及制备方法 |
WO2020015698A1 (zh) | 2018-07-19 | 2020-01-23 | 江苏恒瑞医药股份有限公司 | 一种凝血因子XIa抑制剂及其中间体的制备方法 |
EP3741746A4 (en) * | 2018-02-27 | 2020-12-16 | Jiangsu Hengrui Medicine Co., Ltd. | CRYSTAL FORM OF OXOPICOLINAMIDE DERIVATIVE AND MANUFACTURING PROCESS FOR IT |
TWI722466B (zh) * | 2019-07-01 | 2021-03-21 | 大陸商江蘇恒瑞醫藥股份有限公司 | 氧代吡啶醯胺類衍生物的晶型及製備方法 |
WO2021057818A1 (zh) | 2019-09-27 | 2021-04-01 | 深圳信立泰药业股份有限公司 | FXIa抑制剂及其制备方法和医药用途 |
CN112675173A (zh) * | 2020-12-25 | 2021-04-20 | 华南理工大学 | FXIa抑制剂化合物或其盐的医药用途 |
CN113135929A (zh) * | 2020-01-17 | 2021-07-20 | 江西济民可信集团有限公司 | 呋喃并吡啶酮酰胺化合物及其制备方法和用途 |
TWI749881B (zh) * | 2019-11-21 | 2021-12-11 | 大陸商深圳信立泰藥業股份有限公司 | 二氧代哌類衍生物、其製備方法及其在醫藥上的應用 |
WO2022083706A1 (zh) * | 2020-10-23 | 2022-04-28 | 深圳信立泰药业股份有限公司 | FXIa抑制剂化合物的盐及其制备方法和医药用途 |
WO2022083707A1 (zh) * | 2020-10-23 | 2022-04-28 | 深圳信立泰药业股份有限公司 | FXIa抑制剂化合物或其盐的医药用途 |
WO2022122035A1 (zh) * | 2020-12-11 | 2022-06-16 | 上海领泰生物医药科技有限公司 | 凝血因子XIa抑制剂及其制备方法和应用 |
RU2779013C2 (ru) * | 2018-07-19 | 2022-08-30 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Способ получения ингибитора фактора свертывания крови xia и его интермедиата |
WO2022194225A1 (zh) * | 2021-03-18 | 2022-09-22 | 深圳信立泰药业股份有限公司 | FXIa抑制剂化合物杂质及其制备方法和用途FXIa抑制剂化合物杂质及其制备方法和用途 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190119213A1 (en) * | 2015-03-19 | 2019-04-25 | Bayer Pharma Aktiengesellschaft | Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis |
WO2018041122A1 (zh) * | 2016-08-31 | 2018-03-08 | 江苏恒瑞医药股份有限公司 | 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用 |
US20230083388A1 (en) * | 2018-04-09 | 2023-03-16 | Yale University | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins |
JP2022513919A (ja) * | 2018-12-17 | 2022-02-09 | バイエル・アクチエンゲゼルシヤフト | 血栓性または血小板塞栓性疾患および/または血栓性または血小板塞栓性合併症の治療および/または予防のための置換オキソピリジン誘導体 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104136431A (zh) * | 2011-12-21 | 2014-11-05 | 小野药品工业株式会社 | 作为凝血因子XIa抑制剂的吡啶酮和嘧啶酮衍生物 |
WO2016046156A1 (de) * | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997011695A1 (en) | 1995-09-28 | 1997-04-03 | Merck Sharp & Dohme Limited | Substituted indolylpropyl-piperazine derivatives as 5-ht1dalpha agonists |
WO1996030396A1 (en) | 1995-03-24 | 1996-10-03 | Molecumetics Ltd. | β-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS |
ES2192764T3 (es) | 1998-02-12 | 2003-10-16 | Molecumetics Ltd | Mimeticos de lamina beta y metodos relacionados con el uso de los mismos. |
WO2003064413A1 (en) * | 2002-02-01 | 2003-08-07 | Astrazeneca Ab | Quinazoline compounds |
KR100669587B1 (ko) | 2002-04-26 | 2007-01-15 | 에프. 호프만-라 로슈 아게 | 치환된 페닐아세트아마이드 및 그의 글루코키나제 활성화제로서의 용도 |
AU2003243657A1 (en) | 2002-06-26 | 2004-01-19 | Bristol-Myers Squibb Company | Amino-bicyclic pyrazinones and pyridinones |
US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
TW200635899A (en) | 2004-12-22 | 2006-10-16 | Astrazeneca Ab | Chemical compounds |
US8247556B2 (en) | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
JP2008013527A (ja) | 2006-07-10 | 2008-01-24 | Sankyo Co Ltd | チエノ[3,2−d]ピリミジン−2,4−ジアミン誘導体 |
AU2008340991B2 (en) | 2007-12-21 | 2012-02-23 | University Health Network | Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer |
JP5337259B2 (ja) | 2009-02-26 | 2013-11-06 | レビバ ファーマシューティカルズ,インコーポレーテッド | アリールピペラジン誘導体の組成物、合成および利用方法 |
PL2444395T3 (pl) | 2009-06-19 | 2016-06-30 | D Western Therapeutics Inst Inc | Podstawiona pochodna izochinoliny |
JP2013519673A (ja) | 2010-02-10 | 2013-05-30 | レクシコン ファーマシューティカルズ インコーポレイテッド | 転移性骨疾患の治療のためのトリプトファンヒドロキシラーゼ阻害剤 |
WO2012044090A2 (ko) | 2010-09-29 | 2012-04-05 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
CN102093364B (zh) | 2011-01-07 | 2015-01-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
US9259000B2 (en) | 2011-02-28 | 2016-02-16 | Riken | Auxin biosynthesis inhibitor |
US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
JP6247632B2 (ja) | 2011-06-19 | 2017-12-13 | ヴィアメット ファーマスーティカルズ,インコーポレイテッド | メタロ酵素阻害剤化合物 |
CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
WO2013042782A1 (ja) | 2011-09-22 | 2013-03-28 | 武田薬品工業株式会社 | 縮合複素環化合物 |
CN103987696B (zh) | 2011-10-14 | 2016-12-21 | 百时美施贵宝公司 | 作为因子xia抑制剂的取代的四氢异喹啉化合物 |
MY165742A (en) | 2011-10-14 | 2018-04-23 | Bristol Myers Squibb Co | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
JP2014532746A (ja) | 2011-11-09 | 2014-12-08 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | バニロイド受容体リガンドとしての、co含有基で置換されたフェニル部分を担持する置換ピラゾリルをベースとするカルボキサミドおよび尿素誘導体 |
JP6154887B2 (ja) | 2012-03-20 | 2017-06-28 | セラゴン ファーマシューティカルズ,インク. | エストロゲン受容体モジュレーターおよびその使用 |
EP2832734A4 (en) | 2012-03-28 | 2015-08-26 | Takeda Pharmaceutical | HETEROCYCLIC CONNECTION |
US20160137639A1 (en) | 2012-10-26 | 2016-05-19 | Japan Tobacco Inc. | Triazole-isoxazole compound and medical use thereof |
WO2014075387A1 (zh) | 2012-11-14 | 2014-05-22 | 上海医药集团股份有限公司 | 一类二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用 |
WO2014100833A1 (en) | 2012-12-21 | 2014-06-26 | Northwestern University | Benzamide compounds and related methods of use |
WO2014135095A1 (en) | 2013-03-06 | 2014-09-12 | Syngenta Participations Ag | Dihydrobenzofuran derivatives as insecticidal compounds |
US9809545B2 (en) * | 2013-03-27 | 2017-11-07 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
TWI633089B (zh) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
US8975417B2 (en) | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
CN103450146B (zh) | 2013-08-27 | 2015-03-11 | 合肥工业大学 | 一种催化合成高纯度4-氯甲基-5-甲基-1,3-二氧杂环戊烯-2-酮的方法 |
JP6368367B2 (ja) | 2013-10-30 | 2018-08-01 | バイエル ファーマ アクチエンゲゼルシャフト | 置換オキソピリジン誘導体 |
MX2016007951A (es) | 2013-12-19 | 2016-09-09 | Gruenenthal Gmbh | Pirrol carboxamidas iv fluorometil-sustituidas. |
KR102502485B1 (ko) | 2014-01-21 | 2023-02-21 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
CN105829298B (zh) * | 2014-02-14 | 2019-02-01 | 四川海思科制药有限公司 | 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用 |
BR112016018564B1 (pt) | 2014-02-14 | 2021-08-31 | Nanjing Scienx Biological Technology Co. Ltd | Formulações ecologicamente favoráveis de benzoato de emamectina e métodos para preparação das mesmas |
TWI659019B (zh) | 2014-02-28 | 2019-05-11 | 日商帝人製藥股份有限公司 | 吡唑醯胺衍生物 |
MA39763A (fr) | 2014-03-20 | 2017-01-25 | Samumed Llc | Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci |
WO2016044626A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2016046159A1 (de) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
WO2016045125A1 (en) | 2014-09-28 | 2016-03-31 | Merck Sharp & Dohme Corp. | Inhibitors of hif prolyl hydroxylase |
WO2016053794A1 (en) | 2014-09-30 | 2016-04-07 | Bristol-Myers Squibb Company | Quinazoline-based kinase inhibitors |
CA2980010C (en) | 2015-03-27 | 2023-10-03 | The Scripps Research Institute | Lipid probes and uses thereof |
JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
CN105348251A (zh) | 2015-12-07 | 2016-02-24 | 东北制药集团股份有限公司 | 一种3,4-亚甲二氧基苯胺的制备方法 |
CN106242941B (zh) | 2016-07-08 | 2019-01-18 | 山东日兴新材料股份有限公司 | 一种环丙基溴甲烷的合成方法 |
WO2018041122A1 (zh) * | 2016-08-31 | 2018-03-08 | 江苏恒瑞医药股份有限公司 | 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用 |
-
2017
- 2017-08-30 WO PCT/CN2017/099579 patent/WO2018041122A1/zh unknown
- 2017-08-30 BR BR112019003557-5A patent/BR112019003557A2/pt active Search and Examination
- 2017-08-30 UA UAA201902875A patent/UA125520C2/uk unknown
- 2017-08-30 US US16/328,128 patent/US10633375B2/en not_active Expired - Fee Related
- 2017-08-30 RU RU2019107938A patent/RU2742771C2/ru active
- 2017-08-30 JP JP2019511336A patent/JP7032814B2/ja active Active
- 2017-08-30 ES ES17845424T patent/ES2903283T3/es active Active
- 2017-08-30 CA CA3031592A patent/CA3031592A1/en active Pending
- 2017-08-30 KR KR1020197007965A patent/KR102416718B1/ko active IP Right Grant
- 2017-08-30 HU HUE17845424A patent/HUE057289T2/hu unknown
- 2017-08-30 MX MX2019001481A patent/MX2019001481A/es unknown
- 2017-08-30 CN CN202111196664.6A patent/CN113929618B/zh active Active
- 2017-08-30 TW TW106129594A patent/TWI756257B/zh active
- 2017-08-30 CN CN201780004214.8A patent/CN108495850B/zh active Active
- 2017-08-30 EP EP17845424.5A patent/EP3486242B1/en active Active
- 2017-08-30 PL PL17845424T patent/PL3486242T3/pl unknown
- 2017-08-30 AU AU2017317988A patent/AU2017317988B2/en not_active Ceased
- 2017-08-30 DK DK17845424.5T patent/DK3486242T3/da active
- 2017-08-30 CN CN202111197415.9A patent/CN113912586B/zh active Active
- 2017-08-30 PT PT178454245T patent/PT3486242T/pt unknown
-
2018
- 2018-11-15 HK HK18114604.9A patent/HK1255566A1/zh unknown
-
2020
- 2020-02-28 US US16/804,180 patent/US11084808B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104136431A (zh) * | 2011-12-21 | 2014-11-05 | 小野药品工业株式会社 | 作为凝血因子XIa抑制剂的吡啶酮和嘧啶酮衍生物 |
WO2016046156A1 (de) * | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
Non-Patent Citations (1)
Title |
---|
See also references of EP3486242A4 * |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3741746A4 (en) * | 2018-02-27 | 2020-12-16 | Jiangsu Hengrui Medicine Co., Ltd. | CRYSTAL FORM OF OXOPICOLINAMIDE DERIVATIVE AND MANUFACTURING PROCESS FOR IT |
US11299462B2 (en) | 2018-02-27 | 2022-04-12 | Jiangsu Hengrui Medicine Co., Ltd. | Crystal form of oxopicolinamide derivative and preparation method therefor |
US11884660B2 (en) | 2018-04-10 | 2024-01-30 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivative |
JP7333336B2 (ja) | 2018-04-10 | 2023-08-24 | バイエル ファーマ アクチエンゲゼルシャフト | 置換オキソピリジン誘導体 |
WO2019197244A1 (en) | 2018-04-10 | 2019-10-17 | Bayer Pharma Aktiengesellschaft | A substituted oxopyridine derivative |
JP2021521132A (ja) * | 2018-04-10 | 2021-08-26 | バイエル ファーマ アクチエンゲゼルシャフト | 置換オキソピリジン誘導体 |
JP2021529201A (ja) * | 2018-07-02 | 2021-10-28 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Jiangsu Hengrui Medicine Co., Ltd. | オキシピリジンアミド誘導体の結晶形およびその調製方法 |
WO2020007256A1 (zh) * | 2018-07-02 | 2020-01-09 | 江苏恒瑞医药股份有限公司 | 一种氧代吡啶酰胺类衍生物的晶型及制备方法 |
US11225462B2 (en) | 2018-07-02 | 2022-01-18 | Jiangsu Hengrui Medicine Co., Ltd. | Crystal forms of oxypyridine amide derivative and preparation method therefor |
CN112004810A (zh) * | 2018-07-02 | 2020-11-27 | 江苏恒瑞医药股份有限公司 | 一种氧代吡啶酰胺类衍生物的晶型及制备方法 |
CN112004810B (zh) * | 2018-07-02 | 2022-04-08 | 江苏恒瑞医药股份有限公司 | 一种氧代吡啶酰胺类衍生物的晶型及制备方法 |
CN111094268A (zh) * | 2018-07-19 | 2020-05-01 | 江苏恒瑞医药股份有限公司 | 一种凝血因子XIa抑制剂及其中间体的制备方法 |
RU2779013C2 (ru) * | 2018-07-19 | 2022-08-30 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Способ получения ингибитора фактора свертывания крови xia и его интермедиата |
WO2020015698A1 (zh) | 2018-07-19 | 2020-01-23 | 江苏恒瑞医药股份有限公司 | 一种凝血因子XIa抑制剂及其中间体的制备方法 |
TWI722466B (zh) * | 2019-07-01 | 2021-03-21 | 大陸商江蘇恒瑞醫藥股份有限公司 | 氧代吡啶醯胺類衍生物的晶型及製備方法 |
CN114206854A (zh) * | 2019-09-27 | 2022-03-18 | 深圳信立泰药业股份有限公司 | FXIa抑制剂及其制备方法和医药用途 |
TWI756848B (zh) * | 2019-09-27 | 2022-03-01 | 大陸商深圳信立泰藥業股份有限公司 | FXIa抑制劑及其製備方法和醫藥用途 |
JP7450024B2 (ja) | 2019-09-27 | 2024-03-14 | シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド | FXIa阻害剤及びその調製方法と医薬用途 |
RU2802878C9 (ru) * | 2019-09-27 | 2023-09-21 | Шэньчжень Салюбрис Фармасьютикалс Ко. Лтд | Ингибиторы fxia, способ их получения и применение в фармацевтике |
RU2802878C1 (ru) * | 2019-09-27 | 2023-09-05 | Шэньчжень Салюбрис Фармасьютикалс Ко. Лтд | Ингибиторы fxia, способ их получения и применение в фармацевтике |
WO2021057818A1 (zh) | 2019-09-27 | 2021-04-01 | 深圳信立泰药业股份有限公司 | FXIa抑制剂及其制备方法和医药用途 |
CN114206854B (zh) * | 2019-09-27 | 2023-02-24 | 深圳信立泰药业股份有限公司 | FXIa抑制剂及其制备方法和医药用途 |
CN116120240A (zh) * | 2019-09-27 | 2023-05-16 | 深圳信立泰药业股份有限公司 | FXIa抑制剂化合物及其制备方法和医药用途 |
JP2022550367A (ja) * | 2019-09-27 | 2022-12-01 | シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド | FXIa阻害剤及びその調製方法と医薬用途 |
AU2020355830B2 (en) * | 2019-09-27 | 2023-04-13 | Shenzhen Salubris Pharmaceuticals Co. Ltd | FXIa inhibitors and preparation method therefor and pharmaceutical use thereof |
TWI749881B (zh) * | 2019-11-21 | 2021-12-11 | 大陸商深圳信立泰藥業股份有限公司 | 二氧代哌類衍生物、其製備方法及其在醫藥上的應用 |
CN113135929A (zh) * | 2020-01-17 | 2021-07-20 | 江西济民可信集团有限公司 | 呋喃并吡啶酮酰胺化合物及其制备方法和用途 |
CN113135929B (zh) * | 2020-01-17 | 2024-04-19 | 江西济民可信集团有限公司 | 呋喃并吡啶酮酰胺化合物及其制备方法和用途 |
CN115427043B (zh) * | 2020-10-23 | 2023-04-07 | 深圳信立泰药业股份有限公司 | FXIa抑制剂化合物或其盐的医药用途 |
CN115427043A (zh) * | 2020-10-23 | 2022-12-02 | 深圳信立泰药业股份有限公司 | FXIa抑制剂化合物或其盐的医药用途 |
WO2022083707A1 (zh) * | 2020-10-23 | 2022-04-28 | 深圳信立泰药业股份有限公司 | FXIa抑制剂化合物或其盐的医药用途 |
WO2022083706A1 (zh) * | 2020-10-23 | 2022-04-28 | 深圳信立泰药业股份有限公司 | FXIa抑制剂化合物的盐及其制备方法和医药用途 |
WO2022122035A1 (zh) * | 2020-12-11 | 2022-06-16 | 上海领泰生物医药科技有限公司 | 凝血因子XIa抑制剂及其制备方法和应用 |
CN117480164A (zh) * | 2020-12-11 | 2024-01-30 | 上海领泰生物医药科技有限公司 | 凝血因子XIa抑制剂及其制备方法和应用 |
CN117480164B (zh) * | 2020-12-11 | 2024-07-05 | 上海领泰生物医药科技有限公司 | 凝血因子XIa抑制剂及其制备方法和应用 |
CN112675173B (zh) * | 2020-12-25 | 2022-04-05 | 华南理工大学 | FXIa抑制剂化合物或其盐的医药用途 |
CN112675173A (zh) * | 2020-12-25 | 2021-04-20 | 华南理工大学 | FXIa抑制剂化合物或其盐的医药用途 |
WO2022194225A1 (zh) * | 2021-03-18 | 2022-09-22 | 深圳信立泰药业股份有限公司 | FXIa抑制剂化合物杂质及其制备方法和用途FXIa抑制剂化合物杂质及其制备方法和用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI756257B (zh) | 吡啶酮醯胺類衍生物、其製備方法及其在醫藥上的應用 | |
CN111377917B (zh) | 杂环类化合物、中间体、其制备方法及应用 | |
CA3029857C (en) | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof | |
TWI714600B (zh) | 哌啶類衍生物、其製備方法及其在醫藥上的應用 | |
TWI718207B (zh) | 苯並呋喃類衍生物、其製備方法及其在醫藥上的應用 | |
KR102057877B1 (ko) | 질소함유 헤테로고리 유도체 및 그의 약물에서의 용도 | |
CN108017603B (zh) | 三环化合物及其用途 | |
CN107793396B (zh) | 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用 | |
WO2022135470A1 (zh) | 作为kras抑制剂的杂环化合物的制备及其应用方法 | |
WO2019223715A1 (zh) | 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用 | |
WO2020192650A1 (zh) | 酰胺类化合物制备方法及其在医药领域的应用 | |
WO2022194269A1 (zh) | 新型egfr降解剂 | |
CN105658641A (zh) | 氮茚-酰胺类衍生物、其制备方法及其在医药上的应用 | |
KR102668958B1 (ko) | 브루톤 티로신 키나아제 억제제인 치환된 1-아미노-1h-이미다졸-5-카르복사미드 | |
CN107200726B (zh) | 吡咯烷-酰胺类衍生物、其制备方法及其在医药上的应用 | |
CN105218564A (zh) | 三环噁唑烷酮类化合物及其制备方法和用途 | |
TW201934558A (zh) | 苯并雜芳基類衍生物、其製備方法及其在醫藥上的應用 | |
WO2023093832A1 (zh) | 三并环衍生物及其制备方法和应用 | |
KR20200125967A (ko) | 수용체 억제제, 이를 포함하는 약학적 조성물 및 그 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17845424 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3031592 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2017317988 Country of ref document: AU Date of ref document: 20170830 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019511336 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017845424 Country of ref document: EP Effective date: 20190213 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019003557 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20197007965 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112019003557 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190221 |